


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PCT/DO-EO**

Commissioner for Patents  
Washington, D.C. 20231

"Express Mail" mailing label number **EK 295 392 146 US**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on February 14, 2001.



Colleen Hanagan

**NATIONAL STAGE APPLICATION TRANSMITTAL LETTER  
APPLICATION FILING UNDER 35 U.S.C. § 371**

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s): **Thonnard, Joelle**  
International Application No.: **PCT/EP99/05989**  
International Published Appln. No.: **WO 00/11182**  
International Filing Date: **13 August 1999**  
Priority Filing Date: **18 August 1998**  
Thirty Month Date: **18 February 2001**  
Title: **"BASB024 OUTER MEMBRANE PROTEIN  
OF NEISSERIA MENINGITIDIS"**

**1. THIS NEW APPLICATION IS A NATIONAL STAGE  
APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR  
EXAMINATION WITHOUT DELAY TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US).**

This is a **FIRST** submission of items concerning a filing under 35 U.S.C. § 371;  
 This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

**2.**  This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

3. A proper Demand for International Preliminary Examination was made by the 19<sup>TH</sup> month from the earliest claimed priority date.

4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):

- One copy of International Publication **WO 00/11182**
- (a)  is transmitted herewith (**required only if not transmitted by the International Bureau**)
- (b)  has been transmitted by the International Bureau
- (c)  is not required, as the application was filed in the United States Receiving Office (RO/US)

**Fees**

The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - **\$860.00**

- Claims in Excess of 20 (20 @ \$18.00)
- Independent Claims in Excess of 3 (4 @ \$80.00)

5. Further enclosed are:

- One copy of International Preliminary Examination Report.
- One copy of International Search Report - (references not available).
- One copy of Written Opinion.
- One copy of PCT Request as filed.
- One copy of Chapter II Demand as filed.

6.  A translation of the International Application into English (35 U.S.C. § 371(c)(2))

7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3))

8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3))

9. Still additional papers enclosed:

- Assignment with Assignment Recordation Form Cover Sheet
- Verification Statement Claiming Small Entity Status
- Declaration or oath is enclosed executed by the inventor
- An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
- Return Acknowledgment Postcard

10. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

A. Enclosed are:

(a)  Computer Readable Copy of the Sequence Listing

(b)  Paper Copy (identical to Computer Readable Copy) of the Sequence Listing

B.  Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows:

U.S. Application No.: @@

Filed: @@

Attorney Docket No.: @@

which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. **Please TRANSFER the sequence listing from the parent to this application.**

C.  Statement under 37 CFR § 1.821(f): **The information recorded in computer readable form is identical to the written Sequence Listing.**

D.  Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): **The submission of the Sequence Listing includes no new matter.**

E.  Amendment: Please enter the Sequence Listing into the application.

11. **Preliminary Amendment**

Prior to calculation of fees, kindly enter:

Preliminary Amendment submitted herewith

do not enter Preliminary Amendment

12. Fee payment being made at this time is enclosed:

* Basic filing fee (\$860.00)	860.00
* Claims in Excess of 20	360.00
* (20 @ \$18.00)	
Independent Claims in Excess of 3	240.00
(4 @ \$80.00)	
* Total Fees enclosed:	<u>\$1460.00</u>

13. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354  
Allen Bloom  
Registration No. 29,135  
Attorney for Applicant

DECHERT  
4000 Bell Atlantic Tower  
1717 Arch Street  
Philadelphia, PA 19103-2793  
Fax: (609) 620-3259  
Attn: Arthur E. Jackson, Esq.  
(609) 620-3254

105886.1.07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thonnard

Serial No.: Unknown

Filed: Herewith

Group Art Unit No.: Unknown

Examiner: Unknown

For: BASB024 Outer Membrane Protein of Neisseria Meningitidis

PRELIMINARY AMENDMENT

Sir:

Please enter this Preliminary Amendment into the record of the above-identified patent application before the calculation of fees.

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor:

29. An isolated polypeptide comprising a member selected from the group consisting of
  - (a) an amino acid sequence which has at least 90% identity to SEQ ID NOs:4 or 6;
  - (b) an immunogenic fragment of the amino acid sequence of (a), wherein the immunogenic fragment is at least 90% identical to an aligned contiguous segment of SEQ ID NOs:4 or 6; and
  - (c) an immunogenic fragment of the amino acid sequence of (a) that matches an aligned contiguous segment of SEQ ID NOs:4 or 6 with no more than five single amino acid substitutions, deletions or additions;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:4 or 6.

30. The isolated polypeptide of claim 29, wherein the immunogenic fragment of (b) comprises at least 15 amino acids.

31. The isolated polypeptide of claim 30, wherein the immunogenic fragment matches an aligned contiguous segment of SEQ ID NOs:4 or 6 with no more than a single amino acid substitution, deletion or addition.

32. The isolated polypeptide of claim 29, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

33. The isolated polypeptide of Claim 29 wherein the amino acid sequence of (a) has at least 95% identity to SEQ ID NOs:4 or 6.

34. The isolated polypeptide of Claim 33 wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NOs:4 or 6.

35. The isolated polypeptide of claim 33 wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NOs:4 or 6.

36 An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

37. A fusion protein comprising the isolated polypeptide of Claim 29.

38. A fusion protein comprising the isolated polypeptide of 36.

39. The isolated polypeptide of Claim 29 wherein the polypeptide is the immunogenic fragment having no more than two single amino acid substitutions, deletions or additions relative to the aligned sequence.

40. The isolated polypeptide of Claim 29 wherein the polypeptide is the immunogenic fragment having no more than one single amino acid substitution, deletion or addition relative to the aligned sequence.

41. The isolated polypeptide of Claim 29 wherein the polypeptide is the immunogenic fragment which matches the aligned sequence.

42. An isolated polypeptide encoded by an isolated first polynucleotide wherein the isolated first polynucleotide hybridizes under stringent conditions to a second polynucleotide which encodes the polypeptide of SEQ ID NOs:4 or 6; wherein stringent conditions comprise overnight incubation at 42° C in a solution comprising: 50% formamide, 5×SSC (150 mM

NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1× SSC at about 65° C; wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:4 or 6.

43. An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.

44. An isolated polynucleotide encoding a polypeptide of Claim 29, wherein the isolated polynucleotide encodes the polypeptide comprising SEQ ID NOs:4 or 6.

45. An isolated polynucleotide comprising the polynucleotide of SEQ ID NOs:3 or 5.

46. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1.

47. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NOs:3 or 5 minus the full complement of any terminal stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to SEQ ID NOs:3 or 5 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NO:3 or 5 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \cdot y)$$

wherein  $x_n$  is the total number of nucleotides in SEQ ID NOs:3 or 5 minus any terminal stop codon,  $y$  is at least 0.95, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer before subtracting the product from  $x_n$ ; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.

48. An expression vector comprising the isolated polynucleotide of Claim 43.

49. A host cell transformed with the expression vector of Claim 48.

50. A process of producing an isolated polypeptide comprising (a) culturing the host cell of Claim 49 under conditions sufficient for the production of the encoded polypeptide and (b) recovering the polypeptide.

51. A nucleic acid vaccine comprising the isolated polynucleotide of Claim 43 and a pharmaceutically acceptable carrier.

52. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence is identical to SEQ ID NOs:3 or 5 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NOs:3 or 5 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein  $x_n$  is the total number of nucleotides in SEQ ID NOs:3 or 5 minus any terminal stop codon,  $y$  is at least 0.95, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer before subtracting the product from  $x_n$ ; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.

53. The isolated polynucleotide of Claim 52 where  $y$  is at least 0.97.

54. The isolated polynucleotide of Claim 52, where  $y$  is at least 0.99.

55. An expression vector comprising the isolated polynucleotide of Claim 52 which codes for a polypeptide that, when administered to a mammal which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:4 or 6.

56. A host cell transformed with the isolated polynucleotide or an expression vector comprising the isolated polynucleotide of Claim 52.

57. A process of producing an isolated polypeptide comprising (a) culturing the host cell of Claim 56 under conditions sufficient for the production of the encoded polypeptide and (b) recovering the polypeptide.

58. A vaccine comprising the polypeptide of Claim 29 and a pharmaceutically acceptable carrier.

59. A vaccine comprising the polypeptide of Claim 36 and a pharmaceutically acceptable carrier.

60. The vaccine of Claim 58, wherein the composition comprises at least one other *Neisseria meningitidis* antigen.

61. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 29.

62. An antibody immunospecific for the polypeptide of Claim 36.

63. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 29.

64. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide of Claim 29, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.

65. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 43.

66. A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 29 and a suitable pharmaceutical carrier.

67. A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 36 and a suitable pharmaceutical carrier.

68. A process for expressing the polynucleotide of Claim 43 comprising transforming a host cell with the expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.

**REMARKS**

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

**Claims**

Claims 1-28 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

New claims 29-68 have been introduced. No new matter is added.


**Support**

Support for the new claims is either obvious, or is as described in the text below. Particularly, support for the recitation of "five single amino acid substitutions, deletions or additions" can be found, for example, at page 6, lines 17-18. Support for compositions of the isolated polypeptide which include an adjuvant recited in the claims can be found, for example, at page 40, lines 18-19. Support for the stringent hybridization conditions may be found, for example, at page 14, lines 10-14. Support for the recitation of sequence relatedness such as those recited in claim 52 can be found in the specification, for example, at page 44, lines 1-25.

**Closing Remarks**

Entry of this Preliminary Amendment prior to calculation of fees and Examination and Allowance of the pending claims is respectfully requested.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354  
Allen Bloom  
Registration No. 29,135  
Attorneys for Applicant

DECHERT PRICE & RHOADS  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Allen Bloom (609) 620-3214  
Arthur E. Jackson (609) 620-3254  
Fax: (609) 620-3259  
Attn: Allen Bloom, Esq.  
(609) 620-3214

## SEQUENCE LISTING

&lt;110&gt; Thonnard, Joelle

&lt;120&gt; Novel Compounds

&lt;130&gt; BM45330

&lt;150&gt; PCT/EP99/05989

&lt;151&gt; 1999-08-13

&lt;150&gt; GB 9818004.5

&lt;151&gt; 1998-08-18

&lt;160&gt; 9

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 2769

&lt;212&gt; DNA

&lt;213&gt; Bacteria

&lt;400&gt; 1

atagatctt	ctttccgggtt	gaagccgatt	tgtttttatc	ttatgggtgt	tatgctatat	60
catcatagtt	atgccgaaga	tgcaaggcg	gcgggcagcg	aggcgcagat	acaggtttt	120
gaagatgtgc	acgtcaaggc	gaagcgcgt	ccgaaaagaca	aaaaagtgtt	taccgatgcg	180
cgtggcgtat	cgaccggcgt	gatataattc	aaatccagcg	aaaacctcg	caacatcgta	240
cgcagcatcc	ccgggtgcgtt	tacacagcaa	gataaaagct	cgggcattgt	gtcttgaat	300
attcgccgcg	acagcgggtt	cgggcgggtc	aatacgtatgg	tggacggcat	cacgcagacc	360
ttttatttgc	cttctaccga	tgccggcagg	gcaggcgggtt	catctcaatt	cgggtcatct	420
gtcgacagca	attttattgc	cggactggat	gtcgtaaaag	gcagcttcag	cggctcggca	480
ggcatcaaca	gccttggcgg	ttcggcgaat	ctgcggactt	taggcgttgg	tgacgtcggt	540
cagggcaata	atacctacgg	cctgctgcta	aaaggtctga	ccggcaccaa	ttcaacccaa	600
ggtatgcga	tggccgcgt	aggtgcgcgc	aatggctgg	aaagcggagc	atctgtcggt	660
gtgttttacg	ggcacagcag	gcgcacgtg	gcccggaaatt	accgcgtgg	ccgcggcggg	720
cagcacatcg	gaaattttgg	cgcggaaatat	ctggAACGGC	gcaaacagcg	atattttgt	780
caagaaggcg	gttgtaaatt	caattccaac	agcggaaaat	gggagcgggg	tttccaaagg	840
ccgtacttgg	aaaccaagt	gtatcaaaaa	tacaatgacc	cccaagaact	gaaaaataac	900
atcgaaggtc	atgacaaaag	ctggcgggaa	aacctggcgc	cgcaatacga	catcaccccc	960
atcgatccgt	ccagcctgaa	gcagcagtgc	gcaggcaatc	tgtttaaatt	ggaatacgac	1020
ggcgtattca	ataaatacac	ggcgaattt	cgcgattta	acacccaaat	cggcagccgc	1080
aaaatcatca	accgcaatta	tcaattcaat	tacggttt	ctttaaactc	atatgccaac	1140
ctcaatctga	ccgcagccta	caattcgggc	aggcagaaat	atccgaaagg	gtcgaagtt	1200
acaggctggg	ggctttaaa	agattttgaa	acctacaaca	acgcggaaat	cctcgacctc	1260
aacaacaccg	ccacccctcc	gctgccccgc	gaaaccggat	tgcaaaacc	tttgggcttc	1320
aattatttcc	acaacgaata	cgcggaaaac	cgctttccg	agaatttgg	gctgttttc	1380
gacggtccgg	atcaggacaa	cgggtttat	tcctatttg	ggcggtttaa	gggcgataaa	1440
gggctgtgc	cccaaaaatc	aaccatcg	caacccggcc	gcagccaata	tttcaacacg	1500
ttctacttgc	atgcccgcgt	caaaaaagac	atttaccgc	taaactacag	caccaattacc	1560
gtcggctacc	gttcggcgg	cgaatatac	ggcttaccgc	gctcgatgc	cgaatttaag	1620
cggcattcg	gagaaaaact	gccgcacata	aagaacatt	gcaaccagag	ctgcggaaatt	1680
tatgaacccg	tattgaaaaa	atacggc	aaagcgcgc	acaaccattc	gtcagcatt	1740
agtgcggact	tcggcgat	tttcatccg	ttcgcgcgt	attcgcgcac	acaccgtat	1800
cccaacatcc	aagaaatgt	tttttccca	atcggcact	ccggcgttca	caccgcctt	1860
aaaccagagc	gcgcaaaac	ttggcaattt	ggcttcaata	cctataaaaa	aggattgtt	1920
aaacaagatg	atacatagg	ataaaaact	gtcggtacc	gcagccgc	cgacaactac	1980
atccacaacg	tttacggaa	atggtggat	ttgaacgg	atattccgag	ctgggtcagc	2040
agcacccggc	ttgcctacac	catccaacac	cgcaatttca	aagacaaagt	acacaaacac	2100
ggtttttagt	tggagctgaa	ttacgattat	gggcgtttt	tcaccaac	ttcttacg	2160

tatcaaaaaaa	gcacgcaacc	gaccaacttc	agcgatgcga	gcgaatcgcc	caacaatgcg	2220
tccaaagaag	accaactcaa	acaaggttat	gggtttagca	gggttccgc	cctgccgcga	2280
gattacggac	gttggaaat	cggtaacgcgc	tgggtggca	acaaactgac	tttggccggc	2340
gcgatgcgct	atttcggcaa	gagcatccgc	gcgacggctg	aagaacgcta	tatcgacggc	2400
accaacgggg	gaaataccag	caatgtccgg	caactggca	agcgttccat	caaacaaaacc	2460
gaaacccttg	cccgccagcc	tttgattttt	gatttttag	ccgcttacga	gccgaagaaa	2520
aaccttattt	tccgcgccga	agtcaaaaat	ctgttcgaca	ggcgttatat	cgatccgctc	2580
gatgcgggca	atgatgcggc	aacgcagcgt	tattacagtt	cgttcgaccc	gaaagacaag	2640
gacgaagaag	taacgtgtaa	tgctgataaa	acgttgtgca	acggcaaata	cggcggcaca	2700
agcaaaagcg	tattgaccaa	tttgcacgc	ggacgcaccc	ttttgataac	gatgagctac	2760
aagtttaa						2769

<210> 2  
<211> 922  
<212> PRT  
<213> Bacteria

<400> 2  
 Met Arg Ser Ser Phe Arg Leu Lys Pro Ile Cys Phe Tyr Leu Met Gly  
   1               5               10               15  
 Val Met Leu Tyr His His Ser Tyr Ala Glu Asp Ala Gly Arg Ala Gly  
   20               25               30  
 Ser Glu Ala Gln Ile Gln Val Leu Glu Asp Val His Val Lys Ala Lys  
   35               40               45  
 Arg Val Pro Lys Asp Lys Lys Val Phe Thr Asp Ala Arg Ala Val Ser  
   50               55               60  
 Thr Arg Gln Asp Ile Phe Lys Ser Ser Glu Asn Leu Asp Asn Ile Val  
   65               70               75               80  
 Arg Ser Ile Pro Gly Ala Phe Thr Gln Gln Asp Lys Ser Ser Gly Ile  
   85               90               95  
 Val Ser Leu Asn Ile Arg Gly Asp Ser Gly Phe Gly Arg Val Asn Thr  
   100              105              110  
 Met Val Asp Gly Ile Thr Gln Thr Phe Tyr Ser Thr Ser Thr Asp Ala  
   115              120              125  
 Gly Arg Ala Gly Gly Ser Ser Gln Phe Gly Ala Ser Val Asp Ser Asn  
   130              135              140  
 Phe Ile Ala Gly Leu Asp Val Val Lys Gly Ser Phe Ser Gly Ser Ala  
   145              150              155              160  
 Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val  
   165              170              175  
 Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Leu Lys Gly  
   180              185              190  
 Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly  
   195              200              205  
 Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly  
   210              215              220  
 His Ser Arg Arg Thr Trp Ala Gln Asn Tyr Arg Val Gly Gly Gly  
   225              230              235              240  
 Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln  
   245              250              255  
 Arg Tyr Phe Val Gln Glu Gly Gly Leu Lys Phe Asn Ser Asn Ser Gly  
   260              265              270  
 Lys Trp Glu Arg Asp Phe Gln Arg Pro Tyr Trp Lys Thr Lys Trp Tyr  
   275              280              285  
 Gln Lys Tyr Asn Asp Pro Gln Glu Leu Gln Lys Tyr Ile Glu Gly His  
   290              295              300  
 Asp Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro  
   305              310              315              320  
 Ile Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys  
   325              330              335  
 Leu Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp  
   340              345              350

Leu Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln  
     355                  360                  365  
 Phe Asn Tyr Gly Leu Ser Leu Asn Ser Tyr Ala Asn Leu Asn Leu Thr  
     370                  375                  380  
 Ala Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe  
     385                  390                  395                  400  
 Thr Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys  
     405                  410                  415  
 Ile Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr  
     420                  425                  430  
 Glu Leu Gln Thr Thr Leu Gly Phe Asn Tyr Phe His Asn Glu Tyr Gly  
     435                  440                  445  
 Lys Asn Arg Phe Pro Glu Glu Leu Gly Leu Phe Phe Asp Gly Pro Asp  
     450                  455                  460  
 Gln Asp Asn Gly Leu Tyr Ser Tyr Leu Gly Arg Phe Lys Gly Asp Lys  
     465                  470                  475                  480  
 Gly Leu Leu Pro Gln Lys Ser Thr Ile Val Gln Pro Ala Gly Ser Gln  
     485                  490                  495  
 Tyr Phe Asn Thr Phe Tyr Phe Asp Ala Ala Leu Lys Lys Asp Ile Tyr  
     500                  505                  510  
 Arg Leu Asn Tyr Ser Thr Asn Thr Val Gly Tyr Arg Phe Gly Gly Glu  
     515                  520                  525  
 Tyr Thr Gly Tyr Tyr Gly Ser Asp Asp Glu Phe Lys Arg Ala Phe Gly  
     530                  535                  540  
 Glu Asn Ser Pro Thr Tyr Lys Lys His Cys Asn Gln Ser Cys Gly Ile  
     545                  550                  555                  560  
 Tyr Glu Pro Val Leu Lys Lys Tyr Gly Lys Lys Arg Ala Asn Asn His  
     565                  570                  575  
 Ser Val Ser Ile Ser Ala Asp Phe Gly Asp Tyr Phe Met Pro Phe Ala  
     580                  585                  590  
 Ser Tyr Ser Arg Thr His Arg Met Pro Asn Ile Gln Glu Met Tyr Phe  
     595                  600                  605  
 Ser Gln Ile Gly Asp Ser Gly Val His Thr Ala Leu Lys Pro Glu Arg  
     610                  615                  620  
 Ala Asn Thr Trp Gln Phe Gly Phe Asn Thr Tyr Lys Lys Gly Leu Leu  
     625                  630                  635                  640  
 Lys Gln Asp Asp Thr Leu Gly Leu Lys Leu Val Gly Tyr Arg Ser Arg  
     645                  650                  655  
 Ile Asp Asn Tyr Ile His Asn Val Tyr Gly Lys Trp Trp Asp Leu Asn  
     660                  665                  670  
 Gly Asn Ile Pro Ser Trp Val Ser Ser Thr Gly Leu Ala Tyr Thr Ile  
     675                  680                  685  
 Gln His Arg Asn Phe Lys Asp Lys Val His Lys His Gly Phe Glu Leu  
     690                  695                  700  
 Glu Leu Asn Tyr Asp Tyr Gly Arg Phe Phe Thr Asn Leu Ser Tyr Ala  
     705                  710                  715                  720  
 Tyr Gln Lys Ser Thr Gln Pro Thr Asn Phe Ser Asp Ala Ser Glu Ser  
     725                  730                  735  
 Pro Asn Asn Ala Ser Lys Glu Asp Gln Leu Lys Gln Gly Tyr Gly Leu  
     740                  745                  750  
 Ser Arg Val Ser Ala Leu Pro Arg Asp Tyr Gly Arg Leu Glu Val Gly  
     755                  760                  765  
 Thr Arg Trp Leu Gly Asn Lys Leu Thr Leu Gly Gly Ala Met Arg Tyr  
     770                  775                  780  
 Phe Gly Lys Ser Ile Arg Ala Thr Ala Glu Glu Arg Tyr Ile Asp Gly  
     785                  790                  795                  800  
 Thr Asn Gly Gly Asn Thr Ser Asn Val Arg Gln Leu Gly Lys Arg Ser  
     805                  810                  815  
 Ile Lys Gln Thr Glu Thr Leu Ala Arg Gln Pro Leu Ile Phe Asp Phe  
     820                  825                  830  
 Tyr Ala Ala Tyr Glu Pro Lys Lys Asn Leu Ile Phe Arg Ala Glu Val  
     835                  840                  845

Lys Asn Leu Phe Asp Arg Arg Tyr Ile Asp Pro Leu Asp Ala Gly Asn  
 850 855 860  
 Asp Ala Ala Thr Gln Arg Tyr Tyr Ser Ser Phe Asp Pro Lys Asp Lys  
 865 870 875 880  
 Asp Glu Glu Val Thr Cys Asn Ala Asp Lys Thr Leu Cys Asn Gly Lys  
 885 890 895  
 Tyr Gly Gly Thr Ser Lys Ser Val Leu Thr Asn Phe Ala Arg Gly Arg  
 900 905 910  
 Thr Phe Leu Ile Thr Met Ser Tyr Lys Phe  
 915 920

&lt;210&gt; 3

&lt;211&gt; 2769

&lt;212&gt; DNA

&lt;213&gt; Bacteria

&lt;400&gt; 3

atgagatctt	ctttccggtt	gaagccgatt	tgtttttatc	ttatgggtgt	tatgctatat	60
catcatagtt	atgccgaaga	tgcaaggcgc	gcgggcagcg	aggcgcagat	acaggttttg	120
gaagatgtgc	acgtcaaggc	gaagcgcgt	ccgaaagaca	aaaaagtgtt	taccgatgcg	180
cgtccgtat	cgaccgtca	ggatataattc	aaatccagcg	aaaacctcga	caacatcgta	240
cgcacgtcc	ccgggtgcgtt	tacacagcaa	gataaaagct	cgggcattgt	gtctttgaat	300
attcgcggcg	acagcgggtt	cgggcgggtc	aatacgtgg	tgacggcat	cacgcagacc	360
ttttatttcg	cttctaccga	tgccggcagg	gcaggcgggtt	catctcaatt	cggtgcatct	420
gtcgacagca	attttattgc	cgactggat	gtcgtaaag	gcagcttcag	cggctcggca	480
ggcatcaaca	gccttgcgg	ttcggcgaat	ctgcccactt	taggcgttgg	tgacgtcggt	540
cagggcaata	atacctacgg	cctgctgcta	aaagggtctga	ccggcacccaa	ttcaaccaaa	600
ggtaatgcga	tggcggcat	aggtgcgc	aatggctgg	aaagcgggagc	atctgtcggt	660
gtgctttag	ggcacagcag	gcccacgtgt	gcccacaaatt	accgcgttgg	cggcggcggg	720
cagcacatcg	gaaattttgg	cgcggatata	ctggaaacggc	gcaaggcagcg	atattttgt	780
caagaaggcg	ggttgaattt	caattccaaac	agcggaaaaat	gggagcggga	tttccaaagg	840
ccgtacttgg	aaaccaagt	gtatcaaaaa	tacaatgacc	cccaagaact	gcaaaaatac	900
atcaaggtc	atgacaaaag	ctggcgggaa	aacctggcgc	cgcaatacga	catcaccccc	960
atcgatccgt	ccagcctgaa	gcagcagtgc	gcaggaatc	tgtttaaatt	ggaatacgc	1020
ggcgatttca	ataaatacac	ggcgcatttt	cgcgatttaa	acaccaaaaat	cggcagccgc	1080
aaaatcatca	accgcaatta	tcaattcaat	tacggtttat	ctttaaactc	atatgcaac	1140
ctcaatctga	ccgcagcc	caattcggc	aggcagaaat	atccgaaagg	gtcgaagtt	1200
acaggctggg	ggctttaaa	agattttgaa	acctacaaca	acgcggaaaat	cctcgacctc	1260
aacaacaccc	ccaccttccg	gctgccccgc	gaaaccgggt	tgcaaaaccac	tttgggcttc	1320
aattatttcc	acaacgaata	cgccaaaaac	cgctttctg	aagaatttgg	gctgttttc	1380
gacggtccgg	atcaggacaa	cgggctttat	tcctatttgg	ggcggttttaa	gggcgataaa	1440
gggctgtgc	cccaaaaatc	aaccatcg	caaccggcc	gcagccaata	tttcaacacg	1500
ttctacttcg	atgcccgc	caaaaaagac	atttaccgt	taaactacag	caccaatacc	1560
gtcggttacc	gtttcggcgg	cgaatatacg	ggcttattacg	gctcggatga	cgaatttaag	1620
cgggcattcg	gagaaaactc	gccgacatac	aagaaacatt	gcaaccagag	ctgcgaaatt	1680
tatgaacccg	tattgaaaaa	atacggcaaa	aagcgcgcca	acaaccattc	ggtcagcatt	1740
agtgcggact	tcggcgat	tttcatggcg	ttcgccagct	attcgcgcac	acaccgtatg	1800
cccaacatcc	aagaaatgt	tttttccaa	atcggcgact	ccggcggttca	caccgcctt	1860
aaaccagagc	gogcaaaacac	ttggcaattt	ggcttcaata	ccataaaaaa	aggattgtt	1920
aaacaagatg	atacattagg	attaaaact	gtcggttacc	gcagccgc	cgacaactac	1980
atccacaacg	tttacggaa	atgggtggat	ttgaacggg	atattccgag	ctgggtcagc	2040
agcacccggc	ttgcctacac	catccaaacac	cgcaatttca	aagacaaat	acacaaacac	2100
ggtttttagt	tggagctgaa	ttacgattat	gggcgttttt	tcaccaacct	ttcttacgccc	2160
tatcaaaaaa	gcacgcaccc	gaccacttc	agcgatgc	gccaatgc	caacaatgc	2220
tccaaagaag	accacactaa	acaaggttat	gggttggac	gggttccgc	cctgcgcg	2280
gattacggac	gtttgaaat	cggtacgc	ttgttggca	acaaactgac	tttggcggc	2340
gcatgcgtt	atttcgca	gagcatccgc	gcgcacggct	aaaacgc	tatcgacggc	2400
accaacgggg	gaaataccag	caatgtccgg	caactggca	agcgttccat	caaacaaacc	2460
gaaacccttg	cccgccagcc	tttgattttt	gattttacg	ccgcttacga	gccgaagaaa	2520
aaccttattt	tccgcggcga	agtcaaaaat	ctgttcgaca	ggcgttataat	cgatccgctc	2580
gatgcgggca	atgatgcggc	aacgcagcgt	tattacagtt	cggtcgacc	gaaagacaag	2640
gacgaagaag	taacgtgtaa	tgctgataaa	acggttgca	acggcaata	cggcggcaca	2700

agcaaaaagcg tattgaccaa ttttgcacgc ggacgcacct ttttgataac gatgagctac	2760
aagttttaa	2769
<210> 4	
<211> 922	
<212> PRT	
<213> Bacteria	
<400> 4	
Met Arg Ser Ser Phe Arg Leu Lys Pro Ile Cys Phe Tyr Leu Met Gly	
1               5                         10                      15	
Val Met Leu Tyr His His Ser Tyr Ala Glu Asp Ala Gly Arg Ala Gly	
20                                 25                         30	
Ser Glu Ala Gln Ile Gln Val Leu Glu Asp Val His Val Lys Ala Lys	
35                         40                         45	
Arg Val Pro Lys Asp Lys Lys Val Phe Thr Asp Ala Arg Ala Val Ser	
50                         55                         60	
Thr Arg Gln Asp Ile Phe Lys Ser Ser Glu Asn Leu Asp Asn Ile Val	
65                         70                         75                         80	
Arg Ser Ile Pro Gly Ala Phe Thr Gln Gln Asp Lys Ser Ser Gly Ile	
85                         90                         95	
Val Ser Leu Asn Ile Arg Gly Asp Ser Gly Phe Gly Arg Val Asn Thr	
100                        105                         110	
Met Val Asp Gly Ile Thr Gln Thr Phe Tyr Ser Thr Ser Thr Asp Ala	
115                        120                         125	
Gly Arg Ala Gly Gly Ser Ser Gln Phe Gly Ala Ser Val Asp Ser Asn	
130                        135                         140	
Phe Ile Ala Gly Leu Asp Val Val Lys Gly Ser Phe Ser Gly Ser Ala	
145                        150                         155                         160	
Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val	
165                        170                         175	
Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Leu Lys Gly	
180                        185                         190	
Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly	
195                        200                         205	
Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly	
210                        215                         220	
His Ser Arg Arg Ser Val Ala Gln Asn Tyr Arg Val Gly Gly Gly	
225                        230                         235                         240	
Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln	
245                        250                         255	
Arg Tyr Phe Val Gln Glu Gly Leu Lys Phe Asn Ser Asn Ser Gly	
260                        265                         270	
Lys Trp Glu Arg Asp Phe Gln Arg Pro Tyr Trp Lys Thr Lys Trp Tyr	
275                        280                         285	
Gln Lys Tyr Asn Asp Pro Gln Glu Leu Gln Lys Tyr Ile Glu Gly His	
290                        295                         300	
Asp Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro	
305                        310                         315                         320	
Ile Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys	
325                        330                         335	
Leu Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp	
340                        345                         350	
Leu Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln	
355                        360                         365	
Phe Asn Tyr Gly Leu Ser Leu Asn Ser Tyr Ala Asn Leu Asn Leu Thr	
370                        375                         380	
Ala Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe	
385                        390                         395                         400	
Thr Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys	
405                        410                         415	
Ile Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr	

	420	425	430												
Glu	Leu	Gln	Thr	Thr	Leu	Gly	Phe	Asn	Tyr	Phe	His	Asn	Glu	Tyr	Gly
435							440					445			
Lys	Asn	Arg	Phe	Pro	Glu	Glu	Leu	Gly	Leu	Phe	Phe	Asp	Gly	Pro	Asp
450							455				460				
Gln	Asp	Asn	Gly	Leu	Tyr	Ser	Tyr	Leu	Gly	Arg	Phe	Lys	Gly	Asp	Lys
465						470				475				480	
Gly	Leu	Leu	Pro	Gln	Lys	Ser	Thr	Ile	Val	Gln	Pro	Ala	Gly	Ser	Gln
							485			490			495		
Tyr	Phe	Asn	Thr	Phe	Tyr	Phe	Asp	Ala	Ala	Leu	Lys	Lys	Asp	Ile	Tyr
							500			505			510		
Arg	Leu	Asn	Tyr	Ser	Thr	Asn	Thr	Val	Gly	Tyr	Arg	Phe	Gly	Gly	Glu
							515			520			525		
Tyr	Thr	Gly	Tyr	Tyr	Gly	Ser	Asp	Asp	Glu	Phe	Lys	Arg	Ala	Phe	Gly
							530			535			540		
Glu	Asn	Ser	Pro	Thr	Tyr	Lys	Lys	His	Cys	Asn	Gln	Ser	Cys	Gly	Ile
							545			550			555		560
Tyr	Glu	Pro	Val	Leu	Lys	Lys	Tyr	Gly	Lys	Lys	Arg	Ala	Asn	Asn	His
							565			570			575		
Ser	Val	Ser	Ile	Ser	Ala	Asp	Phe	Gly	Asp	Tyr	Phe	Met	Pro	Phe	Ala
							580			585			590		
Ser	Tyr	Ser	Arg	Thr	His	Arg	Met	Pro	Asn	Ile	Gln	Glu	Met	Tyr	Phe
							595			600			605		
Ser	Gln	Ile	Gly	Asp	Ser	Gly	Val	His	Thr	Ala	Leu	Lys	Pro	Glu	Arg
							610			615			620		
Ala	Asn	Thr	Trp	Gln	Phe	Gly	Phe	Asn	Thr	Tyr	Lys	Lys	Gly	Leu	Leu
							625			630			635		640
Lys	Gln	Asp	Asp	Thr	Leu	Gly	Leu	Lys	Leu	Val	Gly	Tyr	Arg	Ser	Arg
							645			650			655		
Ile	Asp	Asn	Tyr	Ile	His	Asn	Val	Tyr	Gly	Lys	Trp	Trp	Asp	Leu	Asn
							660			665			670		
Gly	Asn	Ile	Pro	Ser	Trp	Val	Ser	Ser	Thr	Gly	Leu	Ala	Tyr	Thr	Ile
							675			680			685		
Gln	His	Arg	Asn	Phe	Lys	Asp	Lys	Val	His	Lys	His	Gly	Phe	Glu	Leu
							690			695			700		
Glu	Leu	Asn	Tyr	Asp	Tyr	Gly	Arg	Phe	Phe	Thr	Asn	Leu	Ser	Tyr	Ala
							705			710			715		720
Tyr	Gln	Lys	Ser	Thr	Gln	Pro	Thr	Asn	Phe	Ser	Asp	Ala	Ser	Glu	Ser
							725			730			735		
Pro	Asn	Asn	Ala	Ser	Lys	Glu	Asp	Gln	Leu	Lys	Gln	Gly	Tyr	Gly	Leu
							740			745			750		
Ser	Arg	Val	Ser	Ala	Leu	Pro	Arg	Asp	Tyr	Gly	Arg	Leu	Glu	Val	Gly
							755			760			765		
Thr	Arg	Trp	Leu	Gly	Asn	Lys	Leu	Thr	Leu	Gly	Gly	Ala	Met	Arg	Tyr
							770			775			780		
Phe	Gly	Lys	Ser	Ile	Arg	Ala	Thr	Ala	Glu	Glu	Arg	Tyr	Ile	Asp	Gly
							785			790			795		800
Thr	Asn	Gly	Gly	Asn	Thr	Ser	Asn	Val	Arg	Gln	Leu	Gly	Lys	Arg	Ser
							805			810			815		
Ile	Lys	Gln	Thr	Glu	Thr	Leu	Ala	Arg	Gln	Pro	Leu	Ile	Phe	Asp	Phe
							820			825			830		
Tyr	Ala	Ala	Tyr	Glu	Pro	Lys	Lys	Asn	Leu	Ile	Phe	Arg	Ala	Glu	Val
							835			840			845		
Lys	Asn	Leu	Phe	Asp	Arg	Arg	Tyr	Ile	Asp	Pro	Leu	Asp	Ala	Gly	Asn
							850			855			860		
Asp	Ala	Ala	Thr	Gln	Arg	Tyr	Tyr	Ser	Ser	Phe	Asp	Pro	Lys	Asp	Lys
							865			870			875		880
Asp	Glu	Glu	Val	Thr	Cys	Asn	Ala	Asp	Lys	Thr	Leu	Cys	Asn	Gly	Lys
							885			890			895		
Tyr	Gly	Gly	Thr	Ser	Lys	Ser	Val	Leu	Thr	Asn	Phe	Ala	Arg	Gly	Arg
							900			905			910		
Thr	Phe	Leu	Ile	Thr	Met	Ser	Tyr	Lys	Phe						

915

920

<210> 5  
<211> 2766  
<212> DNA  
<213> Bacteria

&lt;400&gt; 5

atgagatctt	ctttccgggtt	gaagccgatt	tgttttacc	ttatgggtgt	tacgctatat	60
cattatagtt	atgccgaaga	tgcagggcgc	gcgggcagcg	aggcgcagat	acaggtttg	120
gaagatgtgc	acgtcaaggc	gaagcgcgt	ccgaaagaca	aaaaagtgtt	taccgatgcg	180
cgtgccgtat	cgaccgcgt	ggatataattc	aatccagcg	aaaacctcg	caacatcgta	240
cgcacatcc	ccggtcgtt	tacacagcaa	gataaaagct	cggcattgt	gtcttgaat	300
attcgcggcg	acagcgggtt	cgggcggtc	aatacgatgg	tggacggcat	cacgcagacc	360
ttttattcga	cttctaccga	tgcgggcagg	gcaggcggtt	catctcaatt	cggtgcacatct	420
gtcgcacagca	attttattgc	cggactggat	gtcgtcaaag	gcagcttcag	cggctcggca	480
ggcatcaaca	gccttgcgg	ttcggcgaat	ctgcggactt	taggcgtgga	tgacgtcggt	540
cagggcaata	atacctacgg	cctgtgtcta	aaaggtctga	ccggcaccaa	ttcaacccaa	600
ggtaatgcga	tggcggcgat	aggtgcgcgc	aatggctgg	aaagcggagc	atctgtcggt	660
gtgcatttacg	ggcacagcag	gcgcagcgt	gcfgcaaaatt	accgcgtggg	cggcggcggg	720
cagcacatcg	gaaattttgg	cgcggatata	ttggAACGGC	gcaagcagcg	atattttgt	780
caagagggtg	cttgaattt	caattccgac	agcggaaaat	gggagcggga	tttacaaaagg	840
caacagtgg	aatacaagcc	gtataaaaat	tacaacaacc	aagaactaca	aaaatacatc	900
gaaggtcatg	acaaaagctg	gcgggaaaac	ctggcggcgc	aatacgacat	cacccccatc	960
gatccgtcca	gcctgaagca	gcagtcggca	ggcaatctgt	ttaaatttgg	atacgacggc	1020
gttataata	aatacacggc	gcaatttcgc	gatttaaaca	ccaaaatcg	cagccgcaaa	1080
atcatcaacc	gcaattatca	gttcaattac	gttggctt	tgaacccgta	taccaacctc	1140
aatctgacgg	cagcctaca	ttcgggcagg	cagaaatatac	cgaaagggtc	gaagtttaca	1200
ggctggggc	ttttaaagga	tttggaaacc	tacaacaacg	cggaaatctt	cgcacccaac	1260
aacaccgcca	ccttccggct	gccccgcgaa	accgagg	tttcccttcaat	gggcttcaat	1320
tatttccaca	acgaatacgg	caaaaaccgc	tttcctgaag	aattggggct	gtttttcgac	1380
ggtcctgatc	aggacaacgg	gttttattcc	tatttgggc	gggttaaggg	cgataaaggg	1440
ctgctgcccc	aaaaatcaac	cattgtccaa	ccggccggca	gccaatattt	caacacgttc	1500
tacattcgatg	ccgcgctcaa	aaaagacatt	taccgcttaa	actacagcac	caataccgtc	1560
ggctaccgtt	tcggcggcga	atatacgggc	tattacggct	cgatgacga	atattaacgg	1620
gcattcgag	aaaactcgcc	gacatacaag	aaacattgca	accggagctg	cgggatttat	1680
gaacccgtat	tgaaaaata	cgcaaaaaag	cgcgcaaca	accattcggt	cagcattagt	1740
gcggacttcg	gcgattattt	catggcggtc	gccagctatt	cgcgacacaca	ccgtatgccc	1800
aacatccaag	aatgtattt	ttcccaaatac	ggcgactccg	gcgttcacac	cgcctaaaa	1860
ccagagcgcg	caaacactt	gcaatttggc	ttcaataacct	ataaaaaagg	attgtaaaa	1920
caagatgata	cattaggatt	aaaactggtc	ggctaccgca	gccgcacatcg	caactacatc	1980
cacaacgttt	acgggaaatg	gtgggatttg	aacgggata	ttccgagctg	ggtcagcagc	2040
accgggcttg	cctacaccat	ccaaacatcgc	aatttcaaag	acaaagtgc	caaacacgg	2100
tttgagttgg	agctgaatta	cgattatggg	cggttttca	ccaaacctt	ttacgcctat	2160
caaaaaagca	cgcaaccgac	caacttcagc	gatgcgagcg	aatcgccca	caatgcgtcc	2220
aaagaagacc	aactcaaaca	aggttatggg	ttgagcaggg	tttccgcctt	gccgcgagat	2280
tacggacgtt	tggaagtcgg	tacgcgttgg	ttgggcaaca	aactgactt	gggcggcgcg	2340
atgcgtatt	tcggcaagag	catccgcgcg	acggctgaag	aacgctatac	cgacggcacc	2400
aacgggggaa	ataccagcaa	tttccggcaa	ctgggcaagc	gttccatcaa	acaaaccgaa	2460
actcttgcctt	gccagcctt	gattttgtat	ttttacggc	cttacgagcc	gaagaaaaac	2520
cttattttcc	gcggcgaagt	aaaaatctg	ttcgcacaggc	gttataatcg	tccgctcgat	2580
gcgggcaatg	atgcggcaac	gcagcgttat	tacagctcg	tgcacccgaa	agacaaggac	2640
gaagacgtaa	cgtgtatgc	tgataaaaacg	ttgtgcacacg	gcaaaatacgg	cggcacaagc	2700
aaaacgttat	tgaccaattt	tgcacgcgga	cgcacccccc	tgataacgat	gagctacaag	2760
ttttaa						2766

<210> 6  
<211> 921  
<212> PRT  
<213> Bacteria

&lt;400&gt; 6

Met Arg Ser Ser Phe Arg Leu Lys Pro Ile Cys Phe Tyr Leu Met Gly  
 1 5 10 15  
 Val Thr Leu Tyr His Tyr Ser Tyr Ala Glu Asp Ala Gly Arg Ala Gly  
 20 25 30  
 Ser Glu Ala Gln Ile Gln Val Leu Glu Asp Val His Val Lys Ala Lys  
 35 40 45  
 Arg Val Pro Lys Asp Lys Lys Val Phe Thr Asp Ala Arg Ala Val Ser  
 50 55 60  
 Thr Arg Gln Asp Ile Phe Lys Ser Ser Glu Asn Leu Asp Asn Ile Val  
 65 70 75 80  
 Arg Ser Ile Pro Gly Ala Phe Thr Gln Gln Asp Lys Ser Ser Gly Ile  
 85 90 95  
 Val Ser Leu Asn Ile Arg Gly Asp Ser Gly Phe Gly Arg Val Asn Thr  
 100 105 110  
 Met Val Asp Gly Ile Thr Gln Thr Phe Tyr Ser Thr Ser Thr Asp Ala  
 115 120 125  
 Gly Arg Ala Gly Gly Ser Ser Gln Phe Gly Ala Ser Val Asp Ser Asn  
 130 135 140  
 Phe Ile Ala Gly Leu Asp Val Val Lys Gly Ser Phe Ser Gly Ser Ala  
 145 150 155 160  
 Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val  
 165 170 175  
 Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Leu Lys Gly  
 180 185 190  
 Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly  
 195 200 205  
 Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly  
 210 215 220  
 His Ser Arg Arg Ser Val Ala Gln Asn Tyr Arg Val Gly Gly Gly  
 225 230 235 240  
 Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln  
 245 250 255  
 Arg Tyr Phe Val Gln Glu Gly Ala Leu Lys Phe Asn Ser Asp Ser Gly  
 260 265 270  
 Lys Trp Glu Arg Asp Leu Gln Arg Gln Gln Trp Lys Tyr Lys Pro Tyr  
 275 280 285  
 Lys Asn Tyr Asn Asn Gln Glu Leu Gln Lys Tyr Ile Glu Gly His Asp  
 290 295 300  
 Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro Ile  
 305 310 315 320  
 Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys Leu  
 325 330 335  
 Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp Leu  
 340 345 350  
 Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln Phe  
 355 360 365  
 Asn Tyr Gly Leu Ser Leu Asn Pro Tyr Thr Asn Leu Asn Leu Thr Ala  
 370 375 380  
 Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe Thr  
 385 390 395 400  
 Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys Ile  
 405 410 415  
 Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr Glu  
 420 425 430  
 Leu Gln Thr Thr Leu Gly Phe Asn Tyr Phe His Asn Glu Tyr Gly Lys  
 435 440 445  
 Asn Arg Phe Pro Glu Glu Leu Gly Leu Phe Phe Asp Gly Pro Asp Gln  
 450 455 460  
 Asp Asn Gly Leu Tyr Ser Tyr Leu Gly Arg Phe Lys Gly Asp Lys Gly  
 465 470 475 480  
 Leu Leu Pro Gln Lys Ser Thr Ile Val Gln Pro Ala Gly Ser Gln Tyr  
 485 490 495

Phe Asn Thr Phe Tyr Phe Asp Ala Ala Leu Lys Lys Asp Ile Tyr Arg  
 500 505 510  
 Leu Asn Tyr Ser Thr Asn Thr Val Gly Tyr Arg Phe Gly Gly Glu Tyr  
 515 520 525  
 Thr Gly Tyr Tyr Gly Ser Asp Asp Glu Phe Lys Arg Ala Phe Gly Glu  
 530 535 540  
 Asn Ser Pro Thr Tyr Lys Lys His Cys Asn Arg Ser Cys Gly Ile Tyr  
 545 550 555 560  
 Glu Pro Val Leu Lys Lys Tyr Gly Lys Lys Arg Ala Asn Asn His Ser  
 565 570 575  
 Val Ser Ile Ser Ala Asp Phe Gly Asp Tyr Phe Met Pro Phe Ala Ser  
 580 585 590  
 Tyr Ser Arg Thr His Arg Met Pro Asn Ile Gln Glu Met Tyr Phe Ser  
 595 600 605  
 Gln Ile Gly Asp Ser Gly Val His Thr Ala Leu Lys Pro Glu Arg Ala  
 610 615 620  
 Asn Thr Trp Gln Phe Gly Phe Asn Thr Tyr Lys Lys Gly Leu Leu Lys  
 625 630 635 640  
 Gln Asp Asp Thr Leu Gly Leu Lys Leu Val Gly Tyr Arg Ser Arg Ile  
 645 650 655  
 Asp Asn Tyr Ile His Asn Val Tyr Gly Lys Trp Trp Asp Leu Asn Gly  
 660 665 670  
 Asp Ile Pro Ser Trp Val Ser Ser Thr Gly Leu Ala Tyr Thr Ile Gln  
 675 680 685  
 His Arg Asn Phe Lys Asp Lys Val His Lys His Gly Phe Glu Leu Glu  
 690 695 700  
 Leu Asn Tyr Asp Tyr Gly Arg Phe Phe Thr Asn Leu Ser Tyr Ala Tyr  
 705 710 715 720  
 Gln Lys Ser Thr Gln Pro Thr Asn Phe Ser Asp Ala Ser Glu Ser Pro  
 725 730 735  
 Asn Asn Ala Ser Lys Glu Asp Gln Leu Lys Gln Gly Tyr Gly Leu Ser  
 740 745 750  
 Arg Val Ser Ala Leu Pro Arg Asp Tyr Gly Arg Leu Glu Val Gly Thr  
 755 760 765  
 Arg Trp Leu Gly Asn Lys Leu Thr Leu Gly Gly Ala Met Arg Tyr Phe  
 770 775 780  
 Gly Lys Ser Ile Arg Ala Thr Ala Glu Glu Arg Tyr Ile Asp Gly Thr  
 785 790 795 800  
 Asn Gly Gly Asn Thr Ser Asn Phe Arg Gln Leu Gly Lys Arg Ser Ile  
 805 810 815  
 Lys Gln Thr Glu Thr Leu Ala Arg Gln Pro Leu Ile Phe Asp Phe Tyr  
 820 825 830  
 Ala Ala Tyr Glu Pro Lys Lys Asn Leu Ile Phe Arg Ala Glu Val Lys  
 835 840 845  
 Asn Leu Phe Asp Arg Arg Tyr Ile Asp Pro Leu Asp Ala Gly Asn Asp  
 850 855 860  
 Ala Ala Thr Gln Arg Tyr Tyr Ser Ser Phe Asp Pro Lys Asp Lys Asp  
 865 870 875 880  
 Glu Asp Val Thr Cys Asn Ala Asp Lys Thr Leu Cys Asn Gly Lys Tyr  
 885 890 895  
 Gly Gly Thr Ser Lys Ser Val Leu Thr Asn Phe Ala Arg Gly Arg Thr  
 900 905 910  
 Phe Leu Ile Thr Met Ser Tyr Lys Phe  
 915 920

<210> 7  
 <211> 30  
 <212> DNA  
 <213> Bacteria

<400> 7  
 gctagctagc agatcttctt tcgggaagaa

<210> 8		
<211> 34		
<212> DNA		
<213> Bacteria		
<400> 8		
ggtcgctcga gaaacttgta gctcatcgat atca		34
<210> 9		
<211> 1000		
<212> DNA		
<213> Bacteria		
<400> 9		
tatccgataa gtttccgtac cgaacagact agattccgc ctgcgcggga atgacgattc	60	
ataagtttcc cgaaattcca acataaccga aacctgacag taaccgttagc aactgaaccg	120	
tcattccac gaaagtggga atctagaaat gaaaagaac agcatttat cgaaaaataac	180	
tgaaaccgaa cagacttagat tccccctgc gcgggaatga cgattcataa gtttccgaa	240	
attccaacat aaccgaaacc tgacagtaac cgttagtaact gaaccgtcat tcccacgaaa	300	
gtggaaatct agaaatgaaa agcaacaggc atttatcgga aataactgga accgaacaga	360	
cctagattcc cgccctgcgc ggaatgacgg ctgcagatgc ccgacggctt ttatagcaga	420	
ttaacaaaaa tcaggacaag gcccgcgagcc acagacagta caaacagtagc ggaaccgatt	480	
cacttggtgc ttccagcacct tagagaatcg ttctcttga gctaaggcga gacaacgcgg	540	
tactggttt tgttaatccg ctatattccg ccatctctaa gatttacagc gatacacggg	600	
taatttaagg aatggccgaa ccgtcattcc cgccaccc ttccatttcc accactttc	660	
gtcattcccg cgccaggccgg aatctagaat ctcggactt cagataatct ttgaatattg	720	
ctgttggttt aagggtttaga ttccccctgc gcgggaatga cgattcataa gtttccgaa	780	
attccaacat aaccgaaacc tgacagtaac cgtagcaaca gagaatcggt ctctttgagc	840	
taaggcgaaa caacgctgta ccggttttt ttaatccact ataaatatcc aattgaaatc	900	
ttcagacggt atatcgaatt tacactttt aatgtttatg ccgcctaaaa aaatgctaatt	960	
atatttctta attgtctgac tgtttattgt tgaggaaat	1000	

PTO/PCT Rec'd 14 FEB 2001  
BASB024 OUTER MEMBRANE PROTEIN OF NEISSERIA MENINGITIDIS

## FIELD OF THE INVENTION

5 This invention relates to polynucleotides, (herein referred to as "BASB024 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB024" or "BASB024 polypeptide(s)"), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the

10 invention relates to diagnostic assays for detecting infection of certain pathogens.

## BACKGROUND OF THE INVENTION

*Neisseria meningitidis* (meningococcus) is a Gram-negative bacterium frequently isolated from the human upper respiratory tract. It occasionally causes invasive bacterial diseases 15 such as bacteremia and meningitis. The incidence of meningococcal disease shows geographical seasonal and annual differences (Schwartz, B., Moore, P.S., Broome, C.V.; Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Most disease in temperate countries is due to strains of serogroup B and varies in incidence from 1-10/100,000/year total population sometimes reaching higher values (Kaczmarski, E.B. (1997), Commun. Dis. 20 Rep. Rev. 7: R55-9, 1995; Scholten, R.J.P.M., Bijlmer, H.A., Poolman, J.T. et al. Clin. Infect. Dis. 16: 237-246, 1993; Cruz, C., Pavez, G., Aguilar, E., et al. Epidemiol. Infect. 105: 119-126, 1990).

Epidemics dominated by serogroup A meningococci, mostly in central Africa, are 25 encountered, sometimes reaching levels up to 1000/100,000/year (Schwartz, B., Moore, P.S., Broome, C.V. Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Nearly all cases as a whole of meningococcal disease are caused by serogroup A, B, C, W-135 and Y meningococci and a tetravalent A, C, W-135, Y polysaccharide vaccine is available (Armand, J., Arminjon, F., Mynard, M.C., Lafaix, C., J. Biol. Stand. 10: 335-339, 1982).

The polysaccharide vaccines are currently being improved by way of chemical conjugating them to carrier proteins (Lieberman, J.M., Chiu, S.S., Wong, V.K., et al. JAMA 275 : 1499-1503, 1996).

5

A serogroup B vaccine is not available, since the B capsular polysaccharide was found to be nonimmunogenic, most likely because it shares structural similarity to host components (Wyle, F.A., Artenstein, M.S., Brandt, M.L. et al. J. Infect. Dis. 126: 514-522, 1972; Finne, J.M., Leinonen, M., Mäkelä, P.M. Lancet ii.: 355-357, 1983).

10

For many years efforts have been initiated and carried out to develop meningococcal outer membrane based vaccines (de Moraes, J.C., Perkins, B., Camargo, M.C. et al. Lancet 340: 1074-1078, 1992; Bjune, G., Hoiby, E.A. Gronnesby, J.K. et al. 338: 1093-1096, 1991). Such vaccines have demonstrated efficacies from 57% - 85% in older children (>4 years) 15 and adolescents.

Many bacterial outer membrane components are present in these vaccines, such as PorA, PorB, Rmp, Opc, Opa, FrpB and the contribution of these components to the observed protection still needs futher definition. Other bacterial outer membrane components have 20 been defined by using animal or human antibodies to be potentially relevant to the induction of protective immunity, such as TbpB and NspA (Martin, D., Cadieux, N., Hamel, J., Brodeux, B.R., J. Exp. Med. 185: 1173-1183, 1997; Lissolo, L., Maître-Wilmotte, C., Dumas, p. et al., Inf. Immun. 63: 884-890, 1995). The mechanisms of protective immunity will involve antibody mediated bactericidal activity and opsonophagocytosis.

25

A bacteremia animal model has been used to combine all antibody mediated mechanisms (Saukkonen, K., Leinonen, M., Abdillahi, H. Poolman, J. T. Vaccine 7: 325-328, 1989). It is generally accepted that the late complement component mediated bactericidal mechanism is

crucial for immunity against meningococcal disease (Ross, S.C., Rosenthal P.J., Berberic, H.M., Densen, P. J. Infect. Dis. 155: 1266-1275, 1987).

The frequency of *Neisseria meningitidis* infections has risen dramatically in the past few  
5 decades. This has been attributed to the emergence of multiply antibiotic resistant strains  
and an increasing population of people with weakened immune systems. It is no longer  
uncommon to isolate *Neisseria meningitidis* strains that are resistant to some or all of the  
standard antibiotics. This phenomenon has created an unmet medical need and demand for  
new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this  
10 organism.

### **SUMMARY OF THE INVENTION**

The present invention relates to BASB024, in particular BASB024 polypeptides and  
15 BASB024 polynucleotides, recombinant materials and methods for their production. In  
another aspect, the invention relates to methods for using such polypeptides and  
polynucleotides, including prevention and treatment of microbial diseases, amongst others.  
In a further aspect, the invention relates to diagnostic assays for detecting diseases  
associated with microbial infections and conditions associated with such infections, such  
20 as assays for detecting expression or activity of BASB024 polynucleotides or  
polypeptides.

Various changes and modifications within the spirit and scope of the disclosed invention  
will become readily apparent to those skilled in the art from reading the following  
25 descriptions and from reading the other parts of the present disclosure.

### **DESCRIPTION OF THE INVENTION**

The invention relates to BASB024 polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of BASB024 of *Neisseria meningitidis*, which is related by amino acid sequence homology to *Serratia marcescens* HasR heme acquisition outer membrane protein. The invention  
5 relates especially to BASB024 having the nucleotide and amino acid sequences set out in SEQ ID NO:1,3,5 and SEQ ID NO:2,4,6 respectively. It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including  
10 ribopolynucleotides.

### Polypeptides

In one aspect of the invention there are provided polypeptides of *Neisseria meningitidis* referred to herein as "BASB024" and "BASB024 polypeptides" as well as biologically, 15 diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 20 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2, 4, 6;
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to 25 SEQ ID NO:1, 3, 5 over the entire length of SEQ ID NO:1, 3, 5 respectively; or
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:2, 4, 6;

The BASB024 polypeptides provided in SEQ ID NO:2,4,6 are the BASB024 polypeptides from *Neisseria meningitidis* strains ATCC13090 and H44/76.

5     The invention also provides an immunogenic fragment of a BASB024 polypeptide, that  
is, a contiguous portion of the BASB024 polypeptide which has the same or substantially  
the same immunogenic activity as the polypeptide comprising the amino acid sequence of  
SEQ ID NO:2,4,6. That is to say, the fragment (if necessary when coupled to a carrier) is  
capable of raising an immune response which recognises the BASB024 polypeptide.

10    Such an immunogenic fragment may include, for example, the BASB024 polypeptide  
lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-  
terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB024  
according to the invention comprises substantially all of the extracellular domain of a  
polypeptide which has at least 85% identity, more preferably at least 90% identity, yet  
15    more preferably at least 95% identity, most preferably at least 97-99% identity, to that  
of SEQ ID NO:2,4,6 over the entire length of SEQ ID NO:2

A fragment is a polypeptide having an amino acid sequence that is entirely the same as part  
but not all of any amino acid sequence of any polypeptide of the invention. As with  
20    BASB024 polypeptides, fragments may be "free-standing," or comprised within a larger  
polypeptide of which they form a part or region, most preferably as a single continuous  
region in a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an  
25    amino acid sequence of SEQ ID NO:2,4,6 or of variants thereof, such as a continuous series  
of residues that includes an amino- and/or carboxyl-terminal amino acid sequence.  
Degradation forms of the polypeptides of the invention produced by or in a host cell, are  
also preferred. Further preferred are fragments characterized by structural or functional  
attributes such as fragments that comprise alpha-helix and alpha-helix forming regions.

beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

5

Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:2,4,6, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or

10 deleted from the amino acid sequence of SEQ ID NO:2,4,6.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the

15 invention.

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

20 The polypeptides, or immunogenic fragments, of the invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability  
25 during recombinant production. Furthermore, addition of exogenous polypeptide or lipid tail or polynucleotide sequences to increase the immunogenic potential of the final molecule is also considered.

In one aspect, the invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa.

Furthermore, this invention relates to processes for the preparation of these fusion

10 proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

15 The proteins may be chemically conjugated, or expressed as recombinant fusion proteins allowing increased levels to be produced in an expression system as compared to non-fused protein. The fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native  
20 recombinant protein. Preferably the fusion partner will be both an immunological fusion partner and expression enhancing partner.

Fusion partners include protein D from *Haemophilus influenzae* and the non-structural protein from influenzae virus, NS1 (hemagglutinin). Another fusion partner is the  
25 protein known as LytA. Preferably the C terminal portion of the molecule is used. LytA is derived from *Streptococcus pneumoniae* which synthesize an N-acetyl-L-alanine amidase, amidase LytA, (coded by the lytA gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LytA protein is responsible for the affinity to

the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E.coli* C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 5 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions,

10 whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

15 Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

20 It is most preferred that a polypeptide of the invention is derived from *Neisseria meningitidis*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

25 **Polynucleotides**  
It is an object of the invention to provide polynucleotides that encode BASB024 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB024.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB024 polypeptides comprising a sequence set out in SEQ ID NO:1,3,5 which includes a full length gene, or a variant thereof.

5

The BASB024 polynucleotides provided in SEQ ID NO:1,3,5 are the BASB024 polynucleotides from *Neisseria meningitidis* strains ATCC13090 and H44/76.

As a further aspect of the invention there are provided isolated nucleic acid molecules 10 encoding and/or expressing BASB024 polypeptides and polynucleotides, particularly *Neisseria meningitidis* BASB024 polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, 15 diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB024 polypeptide having a deduced amino acid sequence of SEQ ID NO:2,4,6 and polynucleotides closely related thereto and variants thereof.

20

In another particularly preferred embodiment of the invention there is a BASB024 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:2,4,6 or a variant thereof.

25 Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:1, 3, 5 a polynucleotide of the invention encoding BASB024 polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a

polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:1,3,5, typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70).

Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:1,3,5 was discovered in a DNA library derived from *Neisseria meningitidis*.

Moreover, each DNA sequence set out in SEQ ID NO:1,3,5 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:2, 4, 6 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:1, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2767 of SEQ ID NO:1, encodes the polypeptide of SEQ ID NO:2.

The polynucleotide of SEQ ID NO:3, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2767 of SEQ ID NO:3, encodes the polypeptide of SEQ ID NO:4.

The polynucleotide of SEQ ID NO:5, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2764 of SEQ ID NO:5, encodes the polypeptide of SEQ ID NO:6.

5 In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

(a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1,3,5 over the entire length of SEQ ID  
10 NO:1,3,5 respectively; or

(b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:2, 4, 6 over the entire length of SEQ ID NO:2, 4, 6 respectively.

15 A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS  
20 concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO: 1, 3, 5 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding  
25 sequence (open reading frame) in SEQ ID NO: 1, 3, 5. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one

non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

5    The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

10   The nucleotide sequence encoding BASB024 polypeptide of SEQ ID NO:2, 4, 6 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 2766 of SEQ ID NO:1, or the polypeptide encoding sequence contained in nucleotides 1 to 2766 of SEQ ID NO:3, or the polypeptide encoding sequence contained in nucleotides 1 to 2763 of SEQ ID NO:5, respectively. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2, 4, 6.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria meningitidis* BASB024 having an amino acid sequence set out in SEQ ID NO:2, 4, 6. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an

integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode  
5 variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4, 6. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB024  
10 variants, that have the amino acid sequence of BASB024 polypeptide of SEQ ID NO:2, 4, 6 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of BASB024 polypeptide.

15 Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB024 polypeptide having an amino acid sequence set out in SEQ ID NO:2, 4, 6, and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90%  
20 identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

25 Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of SEQ ID NO:1, 3, 5.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB024 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:1, 3, 5.

5 The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity  
10 between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C.  
15 Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.  
20 The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1, 3, 5 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1, 3, 5 or a fragment thereof; and isolating said polynucleotide sequence.  
25 Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for

RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB024 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB024 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at 5 least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB024 gene may be isolated by screening using a DNA sequence

10 provided in SEQ ID NO:1, 3, 5 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

15 There are several methods available and well known to those skilled in the art to obtain full-length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, *et al.*, *PNAS USA* 85: 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the 20 search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using "nested" primers, that is, primers 25 designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly

to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

5 The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.

The polynucleotides of the invention that are oligonucleotides derived from a sequence of SEQ ID NOS:1 – 6 may be used in the processes herein as described, but preferably for 10 PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

15 The invention also provides polynucleotides that encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may 20 facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

For each and every polynucleotide of the invention there is provided a polynucleotide 25 complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed

such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may  
5 also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

10

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or  
15 more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

20

In accordance with an aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* (1992) 1: 363, Manthorpe *et al.*, *Hum. Gene Ther.* (1983) 4:  
25 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* (1989) 264: 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, (1986) 83: 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* (1989) 243: 375), particle bombardment (Tang *et al.*,

*Nature* (1992) 356:152, Eisenbraun *et al.*, *DNA Cell Biol* (1993) 12: 791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* (1984) 81: 5849).

5      **Vectors, Host Cells, Expression Systems**

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived

10     from the DNA constructs of the invention.

Recombinant polypeptides of the present invention may be prepared by processes well known in those skilled in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to

15     expression systems that comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.

For recombinant production of the polypeptides of the invention, host cells can be  
20     genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*,  
*BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook, *et al.*,  
*MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor  
25     Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomycetes, cyanobacteria, *Bacillus subtilis*, *Moraxella catarrhalis*, *Haemophilus influenzae* and *Neisseria meningitidis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, a basidiomycete, *Candida albicans* and *Aspergillus*; insect cells such as cells of *Drosophila S2* and *Spodoptera Sf9*; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

In recombinant expression systems in eukaryotes, for secretion of a translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, 5 hydroxylapatite chromatography and lectin chromatography. Most preferably, ion metal affinity chromatography (IMAC) is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

10 The expression system may also be a recombinant live microorganism, such as a virus or bacterium. The gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g; vaccinia, fowlpox, canarypox), 15 alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), Listeria, Salmonella , Shigella, Neisseria, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

20

#### **Diagnostic, Prognostic, Serotyping and Mutation Assays**

This invention is also related to the use of BASB024 polynucleotides and polypeptides of the invention for use as diagnostic reagents. Detection of BASB024 polynucleotides and/or polypeptides in a eukaryote, particularly a mammal, and especially a human, will provide a 25 diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB024 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.

Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or 5 may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a 10 change in size of the amplified product in comparison to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB024 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more significantly mismatched 15 duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by 20 direct DNA or RNA sequencing. See, for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

25 In another embodiment, an array of oligonucleotides probes comprising BASB024 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of, for example, genetic mutations, serotype, taxonomic classification or identification. Array technology methods are well known and have general applicability and can be used to

address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see, for example, Chee *et al.*, *Science*, 274: 610 (1996)).

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- 5     (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:1, 3, 5, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, 4, 6 or a fragment thereof; or
- 10    (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2, 4, 6.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease,  
15 among others.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of a polynucleotide of the invention, preferable, SEQ ID NO:1, 3, 5, which is associated with a disease or pathogenicity will  
20 provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a course of disease, a determination of a stage of disease, or a susceptibility to a disease, which results from under-expression, over-expression or altered expression of the polynucleotide. Organisms, particularly infectious organisms, carrying mutations in such polynucleotide may be detected at the polynucleotide level by a variety of techniques, such  
25 as those described elsewhere herein.

Cells from an organism carrying mutations or polymorphisms (allelic variations) in a polynucleotide and/or polypeptide of the invention may also be detected at the polynucleotide or polypeptide level by a variety of techniques, to allow for serotyping, for

example. For example, RT-PCR can be used to detect mutations in the RNA. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding 5 BASB024 polypeptide can be used to identify and analyze mutations.

The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying 10 BASB024 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then be subject to various techniques for elucidation of the polynucleotide sequence. In this way, mutations in the polynucleotide sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

15 The invention further provides a process for diagnosing disease, preferably bacterial infections, more preferably infections caused by *Neisseria meningitidis*, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of SEQ ID NO:1, 3, 5. 20 Increased or decreased expression of a BASB024 polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods.

25 In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB024 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a BASB024 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include

radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

The polynucleotides of the invention may be used as components of polynucleotide arrays, preferably high density arrays or grids. These high density arrays are particularly useful for diagnostic and prognostic purposes. For example, a set of spots each comprising a different gene, and further comprising a polynucleotide or polynucleotides of the invention, may be used for probing, such as using hybridization or nucleic acid amplification, using a probe obtained or derived from a bodily sample, to determine the presence of a particular polynucleotide sequence or related sequence in an individual. Such a presence may indicate the presence of a pathogen, particularly *Neisseria meningitidis*, and may be useful in diagnosing and/or prognosing disease or a course of disease. A grid comprising a number of variants of the polynucleotide sequence of SEQ ID NO:1, 3, 5 are preferred. Also preferred is a grid comprising a number of variants of a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2, 4, 6.

### **Antibodies**

The polypeptides and polynucleotides of the invention or variants thereof, or cells expressing the same can be used as immunogens to produce antibodies immunospecific for such polypeptides or polynucleotides respectively.

In certain preferred embodiments of the invention there are provided antibodies against BASB024 polypeptides or polynucleotides.

Antibodies generated against the polypeptides or polynucleotides of the invention can be obtained by administering the polypeptides and/or polynucleotides of the invention, or epitope-bearing fragments of either or both, analogues of either or both, or cells expressing either or both, to an animal, preferably a nonhuman, using routine protocols. For

preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides or polynucleotides of this invention. Also, transgenic mice, or other organisms or animals, such as other mammals, 10 may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

Alternatively, phage display technology may be utilized to select antibody genes with binding activities towards a polypeptide of the invention either from repertoires of PCR 15 amplified v-genes of lymphocytes from humans screened for possessing anti-BASB024 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by, for example, chain shuffling (Clackson *et al.*, (1991) *Nature* 352: 628).  
20 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

Thus, among others, antibodies against BASB024-polypeptide or BASB024-polynucleotide 25 may be employed to treat infections, particularly bacterial infections.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized," where the complementarity determining region or regions of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as  
5 described in Jones *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991)  
*Biotechnology* 9, 266-273.

#### Antagonists and Agonists - Assays and Molecules

10 Polypeptides and polynucleotides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

15 The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method  
20 may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by  
25 the presence of the candidate compound is observed. Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be. Further, the screening methods

may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide or polynucleotide of the present invention, to form a mixture, measuring BASB024 polypeptide and/or polynucleotide activity in the mixture, and comparing the BASB024 polypeptide and/or polynucleotide activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and BASB024 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB024 polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB024 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB024 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB024 polypeptide is

reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of BASB024 polypeptide are most likely to be good antagonists. Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase  
5 signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in BASB024  
10 polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for BASB024 agonists is a competitive assay that combines BASB024 and a potential agonist with BASB024-binding molecules, recombinant BASB024 binding molecules, natural substrates or ligands, or substrate or ligand mimetics,  
15 under appropriate conditions for a competitive inhibition assay. BASB024 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of BASB024 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

20 Potential antagonists include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing  
25 BASB024-induced activities, thereby preventing the action or expression of BASB024 polypeptides and/or polynucleotides by excluding BASB024 polypeptides and/or polynucleotides from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists

5 include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of BASB024.

10 In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the  
15 hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such  
20 fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be  
25 used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection. In particular, the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial BASB024 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

In accordance with yet another aspect of the invention, there are provided BASB024 antagonists and agonists, preferably bacteriostatic or bactericidal agonists and antagonists.

The antagonists and agonists of the invention may be employed, for instance, to prevent, inhibit and/or treat diseases.

In a further aspect, the present invention relates to mimotopes of the polypeptide of the invention. A mimotope is a peptide sequence, sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which recognise the native peptide; or is capable of raising antibodies which recognise the native peptide when coupled to a suitable carrier.

Peptide mimotopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus

distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule. For example, the peptides  
5 may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.

10 Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the polypeptides of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number of peptide sequences which mimic the structure of the native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves  
15 share significant sequence homology to the native polypeptide.

### **Vaccines**

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, preferably humans, which comprises  
20 inoculating the individual with BASB024 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Neisseria meningitidis* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention  
25 relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB024 polynucleotide and/or polypeptide, or a fragment or a variant thereof, for expressing BASB024 polynucleotide and/or polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce

antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One example of administering the gene is by accelerating it into the desired cells as a coating on particles 5 or otherwise. Such nucleic acid vector may comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.

A further aspect of the invention relates to an immunological composition that when introduced into an individual, preferably a human, capable of having induced within it an 10 immunological response, induces an immunological response in such individual to a BASB024 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB024 polynucleotide and/or polypeptide encoded therefrom and/or comprises DNA and/or RNA which encodes and expresses an antigen of said BASB024 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the 15 invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity and/or cellular immunity, such as cellular immunity arising from CTL or CD4+ T cells.

A BASB024 polypeptide or a fragment thereof may be fused with co-protein or chemical 20 moiety which may or may not by itself produce antibodies, but which is capable of stabilizing the first protein and producing a fused or modified protein which will have antigenic and/or immunogenic properties, and preferably protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Haemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, or any other relatively large co-protein which solubilizes the protein and 25 facilitates production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system of the organism receiving the protein. The co-protein may be attached to either the amino- or carboxy-terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides and/or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science 5 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof, which have been shown to encode non-variable regions of bacterial cell surface proteins, in polynucleotide constructs used in such genetic

10 immunization experiments in animal models of infection with *Neisseria meningitidis*. Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection, 15 for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Neisseria meningitidis* infection, in mammals, particularly humans.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable 20 carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, 25 buffers, bacteriostatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed

ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

The vaccine formulation of the invention may also include adjuvant systems for  
5 enhancing the immunogenicity of the formulation. Preferably the adjuvant system  
raises preferentially a TH1 type of response.

An immune response may be broadly distinguished into two extreme categories, being a  
humoral or cell mediated immune responses (traditionally characterised by antibody and  
10 cellular effector mechanisms of protection respectively). These categories of response  
have been termed TH1-type responses (cell-mediated response), and TH2-type immune  
responses (humoral response).

Extreme TH1-type immune responses may be characterised by the generation of antigen  
15 specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses.  
In mice TH1-type responses are often characterised by the generation of antibodies of  
the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. TH2-  
type immune responses are characterised by the generation of a broad range of  
immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

20 It can be considered that the driving force behind the development of these two types of  
immune responses are cytokines. High levels of TH1-type cytokines tend to favour the  
induction of cell mediated immune responses to the given antigen, whilst high levels of  
TH2-type cytokines tend to favour the induction of humoral immune responses to the  
25 antigen.

The distinction of TH1 and TH2-type immune responses is not absolute. In reality an  
individual will support an immune response which is described as being predominantly  
TH1 or predominantly TH2. However, it is often convenient to consider the families of

cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173*). Traditionally, TH1-type responses are associated with the production of the INF- $\gamma$  and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of TH1-type immune responses are not produced by T-cells, such as IL-12. In contrast, TH2- type responses are associated with the secretion of IL-4, IL-5, IL-6 and IL-13.

10 It is known that certain vaccine adjuvants are particularly suited to the stimulation of either TH1 or TH2 - type cytokine responses. Traditionally the best indicators of the TH1:TH2 balance of the immune response after a vaccination or infection includes direct measurement of the production of TH1 or TH2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio

15 of antigen specific antibody responses.

Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

20 Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

25 3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10 $\mu$ g - 100 $\mu$ g preferably 25-50 $\mu$ g per dose  
5 wherein the antigen will typically be present in a range 2-50 $\mu$ g per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived from the bark of Quillaja Saponaria Molina. Optionally this may be admixed with 3 De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with a carrier.

10

The method of production of QS21 is disclosed in US patent No. 5,057,540.

Non-reactogenic adjuvant formulations containing QS21 have been described previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have  
15 been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

Further adjuvants which are preferential stimulators of TH1 cell response include immunomodulatory oligonucleotides, for example unmethylated CpG sequences as  
20 disclosed in WO 96/02555.

Combinations of different TH1 stimulating adjuvants, such as those mentioned hereinabove, are also contemplated as providing an adjuvant which is a preferential stimulator of TH1 cell response. For example, QS21 can be formulated together with  
25 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1:5 to 5 : 1 and often substantially 1 : 1. The preferred range for optimal synergy is 2.5 : 1 to 1 : 1 3D-MPL: QS21.

Preferably a carrier is also present in the vaccine composition according to the invention. The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

5 A preferred oil-in-water emulsion comprises a metabolisable oil, such as squalene, alpha tocopherol and Tween 80. In a particularly preferred aspect the antigens in the vaccine composition according to the invention are combined with QS21 and 3D-MPL in such an emulsion. Additionally the oil in water emulsion may contain span 85 and/or lecithin and/or tricaprylin.

10

Typically for human administration QS21 and 3D-MPL will be present in a vaccine in the range of 1 $\mu$ g - 200 $\mu$ g, such as 10-100 $\mu$ g, preferably 10 $\mu$ g - 50 $\mu$ g per dose.

Typically the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Preferably the ratio of squalene: alpha

15 tocopherol is equal to or less than 1 as this provides a more stable emulsion. Span 85 may also be present at a level of 1%. In some cases it may be advantageous that the vaccines of the present invention will further contain a stabiliser.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalane or

20 squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

25

The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers, autoimmune diseases and related conditions. Such a

polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

While the invention has been described with reference to certain BASB024 polypeptides and polynucleotides, it is to be understood that this covers fragments of the naturally occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

10 The antigen can also be delivered in the form of whole bacteria (dead or alive) or as subcellular fractions, these possibilities do include *N.meningitidis* itself.

#### Compositions, kits and administration

In a further aspect of the invention there are provided compositions comprising a BASB024 polynucleotide and/or a BASB024 polypeptide for administration to a cell or to a multicellular organism.

The invention also relates to compositions comprising a polynucleotide and/or a polypeptide discussed herein or their agonists or antagonists. The polypeptides and polynucleotides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide and/or polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

5 The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as  
10 an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide and/or polynucleotide, such  
15 as the soluble form of a polypeptide and/or polynucleotide of the present invention, agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one  
20 or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or  
25 an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present

invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, solutions, powders and the like.

5 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course,  
10 be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the  
15 attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5  
20 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

25 Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted

using standard empirical routines for optimization, as is well understood in the art.

**Sequence Databases, Sequences in a Tangible Medium, and Algorithms**

5 Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a computer readable medium and then using the stored data in a known macromolecular structure program or to search a sequence database using well known searching tools, such  
10 as the GCG program package.

Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such  
15 as identity and similarity analysis, DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.

20 A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and comparing said first polynucleotide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

25 A computer based method is also provided for performing homology identification, said method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and

comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

All publications and references, including but not limited to patents and patent  
5 applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

10

## DEFINITIONS

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing

15 the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993;

*Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM *J.*

20 *Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1):

387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA( Pearson and Lipman Proc. Natl. Acad. Sci. USA 85; 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; 5 Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

10 Comparison matrix: BLOSSUM62 from Henikoff and Henikoff,  
Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)

Gap Penalty: 8

Gap Length Penalty: 2

A program useful with these parameters is publicly available as the "gap" program from

15 Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

20 Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

25

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

15

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the

reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleic acid alterations,  $x_n$  is the total number of nucleic

acids in SEQ ID NO:1,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., •  
is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$   
and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

(2) Polypeptide embodiments further include an isolated polypeptide comprising a  
polypeptide having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to a  
polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may  
be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain  
integer number of amino acid alterations as compared to the reference sequence, wherein  
said alterations are selected from the group consisting of at least one amino acid deletion,  
substitution, including conservative and non-conservative substitution, or insertion, and  
wherein said alterations may occur at the amino- or carboxy-terminal positions of the  
reference polypeptide sequence or anywhere between those terminal positions,  
interspersed either individually among the amino acids in the reference sequence or in one  
or more contiguous groups within the reference sequence, and wherein said number of

amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

5     $n_a \leq x_a - (x_a \bullet y),$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and • is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

5

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.

10 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or  
15 polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

20 "Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA including single and double-stranded regions.

25 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical

variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.

A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Disease(s)" means any disease caused by or related to infection by a bacteria, including , for example, upper respiratory tract infection, invasive bacterial diseases, such as bacteremia and meningitis.

**EXAMPLES:**

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples  
5 are illustrative, but do not limit the invention.

**Example 1: Discovery and confirmatory DNA sequencing of the BASB024 gene from two *N.meningitidis* strains.**

10 **A: BASB024 in *N. meningitidis* serogroup B strain ATCC13090.**

The BASB024 gene of SEQ ID NO:1 was first discovered in the Incyte PathoSeq database containing unfinished genomic DNA sequences of the *N. meningitidis* strain ATCC13090. The translation of the BASB024 polynucleotide sequence, showed in SEQ ID NO:2, showed significant similarity ( 24 % identity in a 837 amino acids overlap) to the *Serratia marcescens* HasR heme acquisition outer membrane protein.  
15 The sequence of the BASB024 gene was further confirmed experimentally. For this purpose, genomic DNA was extracted from  $10^{10}$  cells of the *N.meningitidis* cells (strain ATCC 13090) using the QIAGEN genomic DNA extraction kit (Qiagen GmbH), and 1 $\mu$ g of this material was submitted to Polymerase Chain Reaction DNA amplification  
20 using primers HasR01 (5' - GCT AGC TAG CAG ATC TTC TTT CGG GAA GAA -3') [SEQ ID NO:7] containing an internal *Nhe*I site and HasR02 (5' - GGT CGC TCG AGA AAC TTG TAG CTC ATC GTT ATC A -3') [SEQ ID NO:8] containing an internal *Xho*I site. This PCR product was gel-purified and subjected to DNA sequencing using the Big Dye Cycle Sequencing kit (Perkin-Elmer) and an ABI 373A/PRISM DNA  
25 sequencer. DNA sequencing was performed on both strands with a redundancy of 2 and the full-length sequence was assembled using the SeqMan program from the DNASTAR Lasergene software package. The resulting DNA sequence and deduced polypeptide sequence are shown as SEQ ID NO:3 and SEQ ID NO:4 respectively.

**B: BASB024 in *N. meningitidis* serogroup B strain H44/76.**

The sequence of the BASB024 gene was also determined in another *N. meningitidis* serogroup B strain, the strain H44/76. For this purpose, genomic DNA was extracted from the *N. meningitidis* strain H44/76 using the experimental conditions presented in Example 1. This material (1 $\mu$ g) was then submitted to Polymerase Chain Reaction DNA amplification using primers HasR01 and HasR02 specific for the BASB024 gene. The resulting DNA fragment was obtained, digested by the *NheI/Xba*I restriction endonucleases and inserted into the corresponding sites of the pET-24b cloning/expression vector (Novagen) using standard molecular biology techniques (Molecular Cloning,a Laboratory Manual, Second Edition, Eds: Sambrook, Fritsch & Maniatis, Cold Spring Harbor press 1989). Recombinant pET-24b/BASB024 was then submitted to DNA sequencing using the Big Dyes kit (Applied biosystems) and analyzed on a ABI 373/A DNA sequencer in the conditions described by the supplier.

As a result, the polynucleotide and deduced polypeptide sequences, referred to as SEQ ID NO:5 and SEQ ID NO:6 respectively, were obtained. Using the MegAlign program from the DNASTAR software package, an alignment of the polynucleotide sequences of SEQ ID NO:1, 3 and 5 was performed, and is displayed in Figure 1; a pairwise comparison of identities is summarized in Table 1, showing that the three BASB024 polynucleotide gene sequences are all similar at identity level greater than 98.0 %. Using the same MegAlign program, an alignment of the polypeptide sequences of SEQ ID NO:2, 4 and 6 was performed, and is displayed in Figure 2; a pairwise comparison of identities is summarized in Table 2, showing that the three BASB024 protein sequences are all similar at a identity level greater than 97.0 %.

Taken together, these data indicate strong sequence conservation of the BASB024 gene among the two *N.meningitidis* serogroup B strains.

**Table 1: Pairwise identities of the BASB024 polynucleotide sequences ( in % )**

	SeqID No:3	SeqID No:5
SeqID No:1	99.8	98.0
SeqID No:3		98.2

5   **Table 2: Pairwise identities of the BASB024 polypeptide sequences ( in % )**

	SeqID No:4	SeqID No:6
SeqID No:2	99.8	97.7
SeqID No:4		97.9

10   **Example 2: Expression and purification of recombinant BASB024 protein in**  
***Escherichia coli.***

The construction of the pET-24b/BASB024 cloning/expression vector was described in Example 1B. This vector harbours the BASB024 gene isolated from the strain H44/76 in fusion with a stretch of 6 Histidine residues, placed under the control of the strong bacteriophage T7 gene 10 promoter. For expression study, this vector was introduced into the *Escherichia coli* strain Novablue (DE3) (Novagen), in which, the gene for the T7 polymerase is placed under the control of the isopropyl-beta-D thiogalactoside (IPTG)-regulatable *lac* promoter. Liquid cultures (100 ml) of the Novablue (DE3) [pET-24b/BASB024] *E. coli* recombinant strain were grown at 37°C under agitation until the optical density at 600nm (OD600) reached 0.6. At that time-point, IPTG was added at a final concentration of 1mM and the culture was grown for 4 additional hours. The

culture was then centrifuged at 10,000 rpm and the pellet was frozen at -20°C for at least 10 hours. As presented in Figure 3, SDS PAGE and immuno-blotting (anti-His mAb) analysis of induced bacterial protein extracts detected an IPTG-inducible recombinant protein of ~ 85kDa.

5 Legend for Figure 3: Substantially pure (more than 80%) BASB024 protein fractions were obtained on a 4-20% gradient polyacrylamide gel (NOVEX) under SDS-PAGE conditions in parallel to a protein molecular weight marker. Gels were either stained with Coomassie Blue R250 or analyzed by western blot using an anti-(His5) monoclonal antibody. (Non-in. stands for non-induced bacterial cultures, In. stands for  
10 induced bacterial cultures).

After thawing, the pellet (2 litre culture) was resuspended during 30 minutes at 22°C in 20 mM phosphate buffer pH 7.0 containing 1 mM Pefabloc prior cell lysis by three passes through a French press disruptor. Lysed cells were pelleted 30 min at 15,000 rpm (Beckman J2-HS centrifuge, JA-20 rotor) at 4°C.

15 BASB024/His6 was solubilised by 6 M Guanidine Chloride, 1 mM Pefabloc, 20 mM phosphate pH 8.0 during 4 hours at 4°C. Cell debris were pelleted 30 min at 15,000 rpm in a JA-20 rotor at 4°C. 0.5 M NaCl was added to the sample before chromatography.

The sample was loaded at a flow-rate of 0.5 ml/min on a 2 ml Ni<sup>2+</sup>-NTA Agarose column (Qiagen). The column was equilibrated in 6 M Guanidine Chloride, 500 mM NaCl, 20 mM phosphate pH 8.0.

20 After passage of the flowthrough, the column was washed with equilibration buffer until the base line was reached and then with 10 column volumes of 20 mM phosphate pH 8.0, 6M Guanidine Chloride, 5 mM Imidazole. The recombinant protein was eluted from the column by 100 mM Imidazole in 6M Guanidine Chloride, 20 mM phosphate pH 8.0, at 1 ml/min.

25 IMAC-eluted sample was dialysed at 4°C versus PBS containing 0.5 M Arginine.

As shown in Figure 4 (lane 5), an enriched (purity estimated at 5% pure in CBB stained SDS-PAGE) BASB024 protein, migrating at 105kDa (estimated relative molecular

mass), was eluted from the column. This polypeptide was reactive against a mouse monoclonal antibody raised against the 5-histidine motif (see Figure 5). Taken together, these data indicate that the BASB024 gene can be expressed and purified under a recombinant form (BASB024/His6) in *E.coli*.

5

Example 3: Presence of anti-BASB024 antibodies in sera from convalescent patients.

10

In this test, several convalescent sera have been tested by western-blotting for recognition of the purified recombinant BASB024 protein.

Briefly, around 10 µg of partially purified BASB024 *N.meningitidis* serogroup B protein are put into a SDS-PAGE gradient gel (4-20%, Novex, code n°EC6028) for 15 electrophoretic migration. Proteins are transferred to nitrocellulose sheet (0.45 µm, Bio-rad code n° 162-0114) at 100 volts for 1 hour using a Bio-rad Trans-blot system (code n°170-3930). Afterwards, filter is blocked with PBS - 0.05 % Tween 20 overnight at room temperature, before incubation with the human sera (these sera are diluted 100 times in PBS - 0.05 % Tween 20) or with anti-pentaHis mouse antibody 20 (Qiagen 34660) (this antibody is diluted 200 times in PBS - 0.05 % Tween 20, and incubated on the nitrocellulose sheet for two hours at room temperature with gentle shaking. After three repeated washing steps in PBS - 0.05 % Tween 20 for 5 min., the nitrocellulose sheet is incubated at room temperature for 1 hour under gentle shaking with the appropriate conjugate (biotinylated anti-human Ig antibodies, from sheep, 25 Amersham code n°RPN1003 or anti-mouse Ig antibodies, Amersham code n°RPN1001 ) diluted at 1/500 in the same washing buffer. The membrane is washed three times as previously, and incubated for 30 min with agitation using the streptavidin-peroxidase complex (Amersham code n°1051) diluted at 1/1000 in the washing buffer. After the last three repeated washing steps, the revelation occurs during the 20 min incubation 30 time in a 50 ml solution containing 30 mg 4-chloro-1-naphthol (Sigma), 10 ml methanol,

40 ml of ultra-pure water, and 30 µl of H<sub>2</sub>O<sub>2</sub>. The staining is stopped while washing the membrane several times in distilled water.

Results illustrated hereafter in Figure 6 show that all the 3 convalescents react against a lot of *E.coli* contaminants, the BASB024 protein being around 10 % pure. However,

5 the recombinant BASB024 protein is clearly visible with the 3 convalescents at around 105 kDa, meaning that all of them recognize this protein after a *Neisseria meningitidis* B infection.. The anti-His tail monoclonal antibody used clearly localize the BASB024 protein on the gel.

10

Example 4 : Analysis of the non-coding flanking regions of the BASB024 gene, and its exploitation for modulated BASB024 gene expression.

The non-coding flanking regions of the BASB024 gene contain regulatory elements  
15 important in the expression of the gene. This regulation takes place both at the transcriptional and translational level. The sequence of these regions, either upstream or downstream of the open reading frame of the gene, can be obtained by DNA sequencing. This sequence information allows the determination of potential regulatory motifs such as the different promoter elements, terminator sequences, inducible  
20 sequence elements, repressors, elements responsible for phase variation, the shine-dalgarno sequence, regions with potential secondary structure involved in regulation, as well as other types of regulatory motifs or sequences.

This sequence information allows the modulation of the natural expression of gene  
BASB024. The upregulation of the gene expression may be accomplished by altering the  
25 promoter, the shine-dalgarno sequence, potential repressor or operator elements, or any other elements involved. Likewise, downregulation of expression can be achieved by similar types of modifications. Alternatively, by changing phase variation sequences, the expression of the gene can be put under phase variation control, or may be uncoupled from this regulation. In another approach, the expression of the gene can be put under the control of

one or more inducible elements allowing regulated expression. Examples of such regulation include, but are not limited to, induction by temperature shift, addition of inductor substrates like selected carbohydrates or their derivatives, trace elements, vitamins, co-factors, metal ions, etc.

5 Such modifications as described above can be introduced by several different means. The modification of sequences involved in gene expression can be done *in vivo* by random mutagenesis followed by selection for the desired phenotype. Another approach consists in isolating the region of interest and modifying it by random mutagenesis, or site-directed mutagenesis, insertion or deletion mutagenesis. The modified region can

10 then be reintroduced into the bacterial genome by homologous recombination, and the effect on gene expression can be assessed. In another approach, the sequence knowledge of the region of interest can be used to replace or delete all or part of the natural regulatory sequences. In this case, the regulatory region targeted is isolated and modified so as to contain the regulatory elements from another gene, a combination of

15 regulatory elements from different genes, a synthetic regulatory region, or any other regulatory region, or to delete selected parts of the wild-type regulatory sequences. These modified sequences can then be reintroduced into the bacterium via homologous recombination into the genome. A non-exhaustive list of preferred promoters that could be used for up-regulation of gene expression includes the promoter *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*.

20 In one example, the expression of the gene can be modulated by exchanging its promoter with a stronger promoter (through isolating the upstream sequence of the gene, *in vitro* modification of this sequence, and reintroduction into the genome by homologous recombination). Upregulated expression can be obtained in both the

25 bacterium as well as in the outer membrane vesicles shed (or made) from the bacterium. In other examples, the described approaches can be used to generate recombinant bacterial strains with improved characteristics for vaccine applications. These can be, but are not limited to, attenuated strains, strains with increased expression of selected antigens, strains with knock-outs (or decreased expression) of genes interfering with the immune response,

strains with modulated expression of immunodominant proteins, strains with modulated shedding of outer-membrane vesicles.

A region directly upstream of the BASB024 gene is given in the sequence of SEQ ID NO:9. This sequence is a further aspect of the invention.

**Deposited materials**

A deposit containing a *Neisseria meningitidis* Serogroup B strain has been deposited with the American Type Culture Collection (herein "ATCC") on June 22, 1997 and assigned 5 deposit number 13090. The deposit was described as *Neisseria meningitidis* (Albrecht and Ghon) and is a freeze-dried, 1.5-2.9 kb insert library constructed from *N. meningitidis* isolate. The deposit is described in Int. Bull. Bacteriol. Nomencl. Taxon. 8: 1-15 (1958).

The *Neisseria meningitidis* strain deposit is referred to herein as "the deposited strain" or as 10 "the DNA of the deposited strain."

The deposited strain contains the full length BASB024 gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any 15 description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the 20 public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

Applicant's or agent's file reference	KP/BM45330	International application No.
---------------------------------------	------------	-------------------------------

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>57</u> , line <u>3-22</u>	
B. IDENTIFICATION OF DEPOSIT	
Name of depositary institution <b>AMERICAN TYPE CULTURE COLLECTION</b>	
Address of depositary institution ( <i>including postal code and country</i> ) 10801 UNIVERSITY BLVD, MANASSAS, VIRGINIA 20110-2209, UNITED STATES OF AMERICA	
Date of deposit <b>22 June 1997 (22.06.1997)</b>	Accession Number <b>13090</b>
C. ADDITIONAL INDICATIONS ( <i>leave blank if not applicable</i> )	
In respect of those designations where a European Patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ( <i>if the indications are not for all designated States</i> )	
E. SEPARATE FURNISHING OF INDICATIONS ( <i>leave blank if not applicable</i> )	
The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )	
<p align="center">For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application  <i>(13090) 13 aug 1999</i>            Authorized officer  <b>Y. Marinus-v.d. Nouweland</b></p>	
<p align="center">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:            Authorized officer</p>	

**CLAIMS:**

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:4 and SEQ ID NO:6.  
5
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:4 and SEQ ID NO:6.  
10
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:4 and SEQ ID NO:6.  
15
4. An isolated polypeptide of SEQ ID NO:4 and SEQ ID NO:6.  
20
5. An isolated polypeptide of SEQ ID NO:2.  
25
6. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 5 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:4 or SEQ ID NO:6.
7. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO: 4 or 6 over the entire length of SEQ ID NO: 4 or 6 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.  
25
8. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO: 4 or 6 over the

entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

9. An isolated polynucleotide which comprises a nucleotide sequence which has at least 5 85% identity to that of SEQ ID NO: 3 or 5 over the entire length of SEQ ID NO: 3 or 5 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

10. The isolated polynucleotide as claimed in any one of claims 7 to 9 in which the identity is at least 95% to SEQ ID NO: 3 or 5.

10

11. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:4 or SEQ ID NO:6.

15

12. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3 or SEQ ID NO:5.

20

13. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:4 or SEQ ID NO:6, obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:3 or SEQ ID NO:5 or a fragment thereof.

25

14. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2.

15. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1.

16. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, obtainable by screening an appropriate library under stringent

hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

17. An expression vector or a recombinant live microorganism comprising an isolated  
5 polynucleotide according to any one of claims 7 - 16.

18. A host cell comprising the expression vector of claim 17 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group  
10 consisting of: SEQ ID NO:4 or SEQ ID NO:6.

19. A process for producing a polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:4 or SEQ ID NO:6 comprising culturing a host cell of claim 18 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.  
15

20. A process for expressing a polynucleotide of any one of claims 7 – 16 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.  
20

21. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.  
25

22. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 16 and a pharmaceutically effective carrier.

23. The vaccine composition according to either one of claims 21 or 22 wherein said composition comprises at least one other *Neisseria meningitidis* antigen.

24. An antibody immunospecific for the polypeptide or immunological fragment as  
5 claimed in any one of claims 1 to 6.

25. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 - 6, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of  
10 having such an infection.

26. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 – 6 in the preparation of a medicament for use in generating an immune response in an animal.  
15

27. Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 7 - 16 in the preparation of a medicament for use in generating an immune response in an animal.

20 28. A therapeutic composition useful in treating humans with *Neisseria meningitidis* disease comprising at least one antibody directed against the polypeptide of claims 1 – 6 and a suitable pharmaceutical carrier.

1/17

**Figure 1 : Alignment of the BASB024 polynucleotide sequences.**  
**Identity to SeqID No:1 is indicated by a dot, and a dash (“-“) indicates a missing nucleotide.**

*	20	*	40	*
Seqid1 :	ATGAGATCTTCTTCGGTTGAAGCCGATTTGTTTATCTTATGGGTGT	:	50	
Seqid3 :	.....	:	50	
Seqid5 :	.....C.....	:	50	

60	*	80	*	100
Seqid1 :	TATGCTATATCATCATAGTTATGCCGAAGATGCAGGGCGCGCGGGCAGCG	:	100	
Seqid3 :	.....	:	100	
Seqid5 :	..C.....T.....	:	100	

*	120	*	140	*
Seqid1 :	AGGCGCAGATAACAGGTTTGGAAAGATGTGCACGTCAAGGCGAAGCGCGTA	:	150	
Seqid3 :	.....	:	150	
Seqid5 :	.....	:	150	

160	*	180	*	200
Seqid1 :	CCGAAAGACAAAAAGTGTACCGATGCGCGTGCCTATCGACCCGTCA	:	200	
Seqid3 :	.....	:	200	
Seqid5 :	.....	:	200	

*	220	*	240	*
Seqid1 :	GGATATATTCAAATCCAGCGAAAACCTCGACAACATCGTACGCAGCATCC	:	250	
Seqid3 :	.....	:	250	
Seqid5 :	.....	:	250	

260	*	280	*	300
Seqid1 :	CCGGTGCCTTACACAGCAAGATAAAAGCTCGGCATTGTGTCTTGAAAT	:	300	
Seqid3 :	.....	:	300	
Seqid5 :	.....	:	300	

2/17

	*	320	*	340	*
Seqid1 :	ATTCGCGGCGACAGCGGGTTCGGGCGGGTCAATACGATGGTGGACGGCAT	:	350		
Seqid3 :	.....	:	350		
Seqid5 :	.....	:	350		

	*	360	*	380	*	400
Seqid1 :	CACGCAGACCTTTATTGACTTCTACCGATGCGGGCAGGGCAGGCGGTT	:	400			
Seqid3 :	.....	:	400			
Seqid5 :	.....	:	400			

	*	420	*	440	*
Seqid1 :	CATCTCAATTGGTGCATCTGTCGACAGCAATTATTGCCGGACTGGAT	:	450		
Seqid3 :	.....	:	450		
Seqid5 :	.....	:	450		

	*	460	*	480	*	500
Seqid1 :	GTCGTCAAAGGCAGCTTCAGCGGCTCGGCAGGCATCAACAGCCTGCCGG	:	500			
Seqid3 :	.....	:	500			
Seqid5 :	.....	:	500			

	*	520	*	540	*
Seqid1 :	TTCGGCGAATCTGGACTTAGGCGTGGATGACGTCGTTCAAGGCAATA	:	550		
Seqid3 :	.....	:	550		
Seqid5 :	.....	:	550		

	*	560	*	580	*	600
Seqid1 :	ATACCTACGGCCTGCTGCTAAAAGGTCTGACCGGCACCAATTCAACCAAA	:	600			
Seqid3 :	.....	:	600			
Seqid5 :	.....	:	600			

	*	620	*	640	*
Seqid1 :	GGTAATGCGATGGCGGGATAGGTGCGCGCAAATGGCTGGAAAGCGGAGC	:	650		

09/762926

WO 00/11182

PCT/EP99/05989

3/17

Seqid3 : ..... : 650  
Seqid5 : ..... : 650

660 \* 680 \* 700  
Seqid1 : ATCTGTCGGTGTGCTTTACGGGCACAGCAGGCCACGTGGCGCAAAATT : 700  
Seqid3 : ..... GCGT ..... : 700  
Seqid5 : ..... GCGT ..... : 700

\* 720 \* 740 \*  
Seqid1 : ACCCGCGTGGCGGGCGGGCAGCACATCGAAATTTGGCGCGAATAT : 750  
Seqid3 : ..... : 750  
Seqid5 : ..... : 750

760 \* 780 \* 800  
Seqid1 : CTGGAACGGCGCAAACAGCGATATTTGTACAAGAAGGCAGGGTTGAAATT : 800  
Seqid3 : ..... G ..... : 800  
Seqid5 : T ..... G ..... G .. T .. CT ..... : 800

\* 820 \* 840 \*  
Seqid1 : CAATTCCAACAGCGGAAAATGGGAGCGGGATTCCAAAGGCCGTACTGGA : 850  
Seqid3 : ..... : 850  
Seqid5 : ..... G ..... A ..... AAC.G.... : 850

860 \* 880 \* 900  
Seqid1 : AAACCAAGTGGTATCAAAATACAATGACCCCCAAGAACTGCAAAATAC : 900  
Seqid3 : ..... : 900  
Seqid5 : ..TA....CC....A....T....CA....--....A..... : 897

\* 920 \* 940 \*  
Seqid1 : ATCGAAGGTACGACAAAGCTGGCGGGAAAACCTGGCGCCGCAATACGA : 950  
Seqid3 : ..... : 950  
Seqid5 : ..... : 947

4/17

960 \* 980 \* 1000

Seqid1 : CATCACCCCCATCGATCCGTCCAGCCTGAAGCAGCAGTCGGCAGGCAATC : 1000  
Seqid3 : ..... : 1000  
Seqid5 : ..... : 997

\* 1020 \* 1040 \*

Seqid1 : TGTTTAAATTGGAATACGACGGCGTATTCAATAAATACACGGCGCAATTT : 1050  
Seqid3 : ..... : 1050  
Seqid5 : ..... : 1047

1060 \* 1080 \* 1100

Seqid1 : CGCGATTAAACACCAAAATCGGCAGCCGAAAATCATCAACCGCAATTA : 1100  
Seqid3 : ..... : 1100  
Seqid5 : ..... : 1097

\* 1120 \* 1140 \*

Seqid1 : TCAATTCAATTACGGTTATCTTAAACTCATATGCCAACCTCAATCTGA : 1150  
Seqid3 : ..... : 1150  
Seqid5 : ...G.....G....G...C.G...A..... : 1147

1160 \* 1180 \* 1200

Seqid1 : CCGCAGCCTACAATTGGGCAGGCAGAAATATCCGAAAGGGTCGAAGTTT : 1200  
Seqid3 : ..... : 1200  
Seqid5 : ..... : 1197

\* 1220 \* 1240 \*

Seqid1 : ACAGGCTGGGGCTTTAAAAGATTTGAAACCTACAACAAACCGCGAAAAT : 1250  
Seqid3 : ..... : 1250  
Seqid5 : .....G..... : 1247

1260 \* 1280 \* 1300

Seqid1 : CCTCGACCTAACAAACACCGCCACCTTCCGGCTGCCCGCGAAACCGAGT : 1300  
Seqid3 : ..... : 1300  
Seqid5 : ..... : 1297

5/17

\* 1320 \* 1340 \*

Seqid1 : TGCAAACCACCTTGGGCTTCATTATTCACAAACGAATACGGCAAAAC : 1350

Seqid3 : ..... : 1350

Seqid5 : ..... : 1347

1360 \* 1380 \* 1400

Seqid1 : CGCTTCCTGAAGAATTGGGCTGTTTCGACGGTCCGGATCAGGACAA : 1400

Seqid3 : ..... : 1400

Seqid5 : ..... T ..... : 1397

\* 1420 \* 1440 \*

Seqid1 : CGGGCTTATT CCTATTGGGCGGTTAACGGCGATAAAGGGCTGCTGC : 1450

Seqid3 : ..... : 1450

Seqid5 : ..... : 1447

1460 \* 1480 \* 1500

Seqid1 : CCCAAAAATCAACCATCGTCCAACCGGCCGCAGCCAATATTCAACACG : 1500

Seqid3 : ..... : 1500

Seqid5 : ..... T ..... : 1497

\* 1520 \* 1540 \*

Seqid1 : TTCTACTTCGATGCCCGCTCAAAAAGACATTACCGCTTAACTACAG : 1550

Seqid3 : ..... : 1550

Seqid5 : ..... : 1547

1560 \* 1580 \* 1600

Seqid1 : CACCAATACCGTCGGCTACCGTTCGCGGCCGAATATACGGCTATTACG : 1600

Seqid3 : ..... : 1600

Seqid5 : ..... : 1597

\* 1620 \* 1640 \*

Seqid1 : GCTCGGATGACGAATTAAAGCGGGCATTCGGAGAAAACCGCCGACATAC : 1650

6/17

Seqid3 : ..... : 1650  
Seqid5 : ..... : 1647

1660 \* 1680 \* 1700  
Seqid1 : AAGAAACATTGCAACCAGAGCTGCGGAATTTATGAACCCGTATTGAAAAA : 1700  
Seqid3 : ..... : 1700  
Seqid5 : ..... G ..... G ..... : 1697

\* 1720 \* 1740 \*  
Seqid1 : ATACGGCAAAAGCGGCCAACACCATTCGGTAGCATTAGTGCAGACT : 1750  
Seqid3 : ..... : 1750  
Seqid5 : ..... : 1747

1760 \* 1780 \* 1800  
Seqid1 : TCGGCGATTATTCATGCCGTTGCCAGCTATTGCGCACACACCGTATG : 1800  
Seqid3 : ..... : 1800  
Seqid5 : ..... : 1797

\* 1820 \* 1840 \*  
Seqid1 : CCCAACATCCAAGAAATGTATTTCCAAATCGGCAGCTCCGGCGTTCA : 1850  
Seqid3 : ..... : 1850  
Seqid5 : ..... : 1847

1860 \* 1880 \* 1900  
Seqid1 : CACCGCCTTAAAACCAGAGCGCGAACACTGGCAATTGGCTTCAATA : 1900  
Seqid3 : ..... : 1900  
Seqid5 : ..... : 1897

\* 1920 \* 1940 \*  
Seqid1 : CCTATAAAAAGGATTGTTAAAACAAGATGATACTAGGATTAAACTG : 1950  
Seqid3 : ..... : 1950  
Seqid5 : ..... : 1947

09/762926

WO 00/11182

PCT/EP99/05989

7/17

1960 \* 1980 \* 2000

Seqid1 : GTCGGCTACCGCAGCCGCATCGACAACACTACATCCACAAACGTTACGGAA : 2000  
Seqid3 : ..... : 2000  
Seqid5 : ..... : 1997

\* 2020 \* 2040 \*

Seqid1 : ATGGTGGGATTGAACGGGAATATTCCGAGCTGGGTCAAGCAGCACCGGGC : 2050  
Seqid3 : ..... : 2050  
Seqid5 : .....G..... : 2047

2060 \* 2080 \* 2100

Seqid1 : TTGCCTACACCATCCAACACCCGCAATTCAAAGACAAAGTACACAAACAC : 2100  
Seqid3 : ..... : 2100  
Seqid5 : .....T.....G..... : 2097

\* 2120 \* 2140 \*

Seqid1 : GGTTTGAGTTGGAGCTGAATTACGATTATGGCGTTTTCACCAACCT : 2150  
Seqid3 : ..... : 2150  
Seqid5 : ..... : 2147

2160 \* 2180 \* 2200

Seqid1 : TTCTTACGCCTATCAAAAAGCACGCAACCGACCAACTCAGCGATGCGA : 2200  
Seqid3 : ..... : 2200  
Seqid5 : ..... : 2197

\* 2220 \* 2240 \*

Seqid1 : GCGAATGCCAACAAATGCGTCAAAGAAGACCAACTCAAACAAGGTTAT : 2250  
Seqid3 : ..... : 2250  
Seqid5 : ..... : 2247

2260 \* 2280 \* 2300

Seqid1 : GGGTTGAGCAGGGTTCCGCCCTGCCGCGAGATTACGGACGTTGGAAGT : 2300  
Seqid3 : ..... : 2300

09/762926

WO 00/11182

PCT/EP99/05989

8/17

Seqid5 : ..... : 2297

\* 2320 \* 2340 \*

Seqid1 : CGGTACGCGCTGGTTGGCAACAAACTGACTTTGGCGGCCGATGCGCT : 2350

Seqid3 : ..... : 2350

Seqid5 : ..... : 2347

2360 \* 2380 \* 2400

Seqid1 : ATTCGGCAAGAGCATCCGCGCAGGGCTGAAGAACGCTATATCGACGGC : 2400

Seqid3 : ..... : 2400

Seqid5 : ..... : 2397

\* 2420 \* 2440 \*

Seqid1 : ACCAACGGGGAAATACCAGCAATGTCCGGCACTGGGCAAGCGTCCAT : 2450

Seqid3 : ..... : 2450

Seqid5 : ..... T ..... : 2447

2460 \* 2480 \* 2500

Seqid1 : CAAACAAACCGAAACCCCTTGCCCCGCCAGCCTTGATTTTGATTTTACG : 2500

Seqid3 : ..... : 2500

Seqid5 : ..... T ..... : 2497

\* 2520 \* 2540 \*

Seqid1 : CCGCTTACGAGCCGAAGAAAAACCTTATTTCCGCGCCGAAGTCAAAAT : 2550

Seqid3 : ..... : 2550

Seqid5 : ..... : 2547

2560 \* 2580 \* 2600

Seqid1 : CTGTTCGACAGGCCTTATATCGATCCGCTCGATGCGGGCAATGATGCGGC : 2600

Seqid3 : ..... : 2600

Seqid5 : ..... : 2597

09/762926

WO 00/11182

PCT/EP99/05989

9/17

\* 2620 \* 2640 \*

Seqid1 : AACGCAGCGTTATTACAGTTCGTTCGACCCGAAAGACAAGGACGAAGAAG : 2650

Seqid3 : ..... : 2650

Seqid5 : .....C.....C. : 2647

2660 \* 2680 \* 2700

Seqid1 : TAACGTGTAATGCTGATAAAACGTTGTGCAACGGCAAATACGGCGGCACA : 2700

Seqid3 : ..... : 2700

Seqid5 : ..... : 2697

\* 2720 \* 2740 \*

Seqid1 : AGCAAAAGCGTATTGACCAATTTGCACGCGGACGCACCTTTTGATAAC : 2750

Seqid3 : ..... : 2750

Seqid5 : ..... : 2747

2760

Seqid1 : GATGAGCTACAAGTTTAA : 2769

Seqid3 : ..... : 2769

Seqid5 : ..... : 2766

10/17

**Figure 2 : Alignment of the BASB024 polypeptide sequences.****Identity to SeqID No:2 is indicated by a dot, and a dash ("—") indicates a missing amino acid.**

*	20	*	40	*
Seqid2 :	MRSSFRLKPICFYLMGVMLYHHSYEAEDAGRAGSEAQIQVLEDVHVAKRV			: 50
Seqid4 :	.....			: 50
Seqid6 :	.....T....Y.....			: 50

60	*	80	*	100
Seqid2 :	PKDKKVFTDARAVSTRQDIFKSSENLDNIVRSIPGAFTQQDKSSGIVSLN			: 100
Seqid4 :	.....			: 100
Seqid6 :	.....			: 100

*	120	*	140	*
Seqid2 :	IRGDSGFGRVNTMVDGITQTFYSTSTDAGRAGGSSQFGASVDSNFIAGLD			: 150
Seqid4 :	.....			: 150
Seqid6 :	.....			: 150

160	*	180	*	200
Seqid2 :	VVKGSFSGSAGINSLAGSANLRTLGVDDVVQGNNTYGLLKGLTGTNSTK			: 200
Seqid4 :	.....			: 200
Seqid6 :	.....			: 200

*	220	*	240	*
Seqid2 :	GNAMAAIGARKWLESGASVGVLYGHSSRTWAQNYRVGGGGQHIGNFGAEY			: 250
Seqid4 :	.....SV.....			: 250
Seqid6 :	.....SV.....			: 250

09/762926

WO 00/11182

PCT/EP99/05989

11/17

260 \* 280 \* 300

Seqid2 : LERRKQRYFVQEGLKFNSNSGKWERDFQRPYWKTWYQKYNDPQEIQKY : 300

Seqid4 : ..... : 300

Seqid6 : .....A.....D.....L..QQ..Y.P.KN..N-..... : 299

\* 320 \* 340 \*

Seqid2 : IEGHDKSWREN LAPQYDITPIDPSSLKQQSAGNLFKLEYDGVFNKYTAQF : 350

Seqid4 : ..... : 350

Seqid6 : ..... : 349

360 \* 380 \* 400

Seqid2 : RDLNTKIGSRKIINRNYQFN YGLSLNSYANLNLTAA YNSGRQKYPKGSKF : 400

Seqid4 : ..... : 400

Seqid6 : .....P.T..... : 399

\* 420 \* 440 \*

Seqid2 : TGWGLLKDFETYNNAKILDNNNTATFRLPRETELQTTLGNYFHNEYGKN : 450

Seqid4 : ..... : 450

Seqid6 : ..... : 449

460 \* 480 \* 500

Seqid2 : RFPEELGLFFDGPQDNGLYSYLGRFKGDKGLLPQKSTIVQPAGSQYFNT : 500

Seqid4 : ..... : 500

Seqid6 : ..... : 499

\* 520 \* 540 \*

Seqid2 : FYFDAALKDIYRLNYSTNTVGYRGGEYTGYYGSDEFKRAFGENSPTY : 550

Seqid4 : ..... : 550

Seqid6 : ..... : 549

09/762926

WO 00/11182

PCT/EP99/05989

12/17

560 \* 580 \* 600

Seqid2 : KKHCNQSCGIYEPVLKKYKKRANNHSVSISADFGDYFMPFASYSRTHRM : 600

Seqid4 : ..... : 600

Seqid6 : .....R..... : 599

\* 620 \* 640 \*

Seqid2 : PNIQEMYFSQIGDSGVHTALKPERANTWQFGFNTYKKGLLKQDDTLGLKL : 650

Seqid4 : ..... : 650

Seqid6 : ..... : 649

660 \* 680 \* 700

Seqid2 : VGYRSRIDNYIHNVYWKWWDLNGNIPSWVSSTGLAYTIQHHRNFKDKVHKH : 700

Seqid4 : ..... : 700

Seqid6 : .....D..... : 699

\* 720 \* 740 \*

Seqid2 : GFELELNYDYGRFFTNLNSYAYQKSTQPTNFSDAESPNNASKEDQLKQGY : 750

Seqid4 : ..... : 750

Seqid6 : ..... : 749

760 \* 780 \* 800

Seqid2 : GLSRVSALPRDYGRLEVGTWRWLGNKLTGGAMRYFGKSIRATAEERYIDG : 800

Seqid4 : ..... : 800

Seqid6 : ..... : 799

\* 820 \* 840 \*

Seqid2 : TNGGNTSNVRQLGKRSIKQTETLARQPLIFDFYAAYPEKKNLIFRAEVKN : 850

Seqid4 : ..... : 850

Seqid6 : .....F..... : 849

09/762926

WO 00/11182

PCT/EP99/05989


13/17

	860	*	880	*	900
Seqid2 :	LFDRRYIDPLDAGNDAATQRYYSSFDPKDKDEEVTCNADKTL	CNGKYGGT	:	900	
Seqid4 :	.....				: 900
Seqid6 :	.....	D.	.....		: 899

	*	920	
Seqid2 :	SKSVLTNFARGRTFLITMSYKF	:	922
Seqid4 :	.....	:	922
Seqid6 :	.....	:	921

09/762926 \* 00/11182


14/17

**Figure 3. Expression and purification of recombinant BASB024 in *E. coli*.**

15/17

**Figure 4 : Coomassie stained SDS-PAGE of the purification fractions of BASB024**


1      2      3      4      5



Lanes :      1 : MW : 175, 83, 62, 47.5, 32.5, 25, 16.5, 6.5  
              2 : Start  
              3 : Flowthrough  
              4 : 5 mM imidazole pool  
              5 : BASB024 enriched pool

16/17

**Figure 5 : Western blot of purified recombinant BASB024 protein probed with anti-His antibody**



Lanes :      1 : MW : 175, 83, 62, 47.5, 32.5, 25, 16.5, 6.5  
              2 : Start  
              3 : Flowthrough  
              4 : 5 mM imidazole pool  
              5 : BASB024 enriched pool


09/762926

WO 00/11182

PCT/EP99/05989

17/17

Figure 6 : Anti-BASB024 antibodies in human convalescent sera by western-blotting using native BASB024 into the gel.



**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

BASB024 Outer Membrane Protein of Neisseria Meningitidis

the specification of which (check one)

[ ] is attached hereto.

[X] was filed on 13 August 1999 as Serial No. PCT/EP99/05989  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

**Prior Foreign Application(s)**

Number	Country	Filing Date	Priority Claimed
9818004.5	Great Britain	18 August 1998	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number    Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application

designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 25,308

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Joelle THONNARD

Inventor's Signature: 

Date: 22 February 2007 *BEP*

Residence: Gembloux, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

## SEQUENCE LISTING

&lt;110&gt; SmithKline Beecham Biologicals S.A.

&lt;120&gt; Novel compounds

&lt;130&gt; BM45330

&lt;160&gt; 9

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 2769

&lt;212&gt; DNA

&lt;213&gt; Bacteria

&lt;400&gt; 1

atgagatctt cttccgggtt gaagccgatt tgttttatc ttatgggtgt tatgctatat	60
catcatagtt atgcgcagaaga tgcagggcgc gcgggcagcg aggcgcagat acagggttttgc	120
gaagatgtgc acgtcaaggc gaagcgcgtt ccgaaagaca aaaaagtgtt taccgatgcgc	180
cgtccgttat cgacccgtca ggatataattc aaatccagcg aaaacctcga caacatcgta	240
cgcagcatcc ccgggtgcgtt tacacagcaa gataaaagct cgggcattgt gtctttgaat	300
attcgcggcg acagcgggtt cgggcgggtc aatacgatgg tggacggcat cacgcagacc	360
ttttatttcga ctcttaccga tgcgggcagg gcaggcgggtt catctcaatt cggtgcatct	420
gtcgacagca attttattgc cggactggat gtcgtcaaag gcagcttcag cggctcggca	480
ggcatcaaca gccttgcggg ttcggcgaat ctgcggactt taggcgtgga tgacgtcggtt	540
cagggcaata atacctacgg cctgcgtcta aaaggtctga cgggcaccaa ttcaaccaaa	600
ggtaatgcga tggcggcgat aggtgcgcgc aaatggctgg aaagcggagc atctgtcggt	660
gtgctttacg ggcacagcag gcgcacgtgg gcgcacaaatt accgcgtggg cggcggcg	720
cagcacatcg gaaattttgg cgcgaaat atcgaaacggc gcaaacagcg atattttgtat	780
caagaaggcg ggttgaattt caattccaac agcggaaaat gggagcgggaa ttccaaagg	840
ccgtactgga aaaccaagtgt gtatcaaaaa tacaatgacc cccagaact gaaaaatac	900
atcgaaggc atgacaaaag ctggcgggaa aacctggcgc cgcaatacga catcaccccc	960
atcgatccgt ccagcctgaa gcagcagtcg gcaggcaatc tgtttaatt ggaatacgac	1020

ggcgttattca ataaaatacac ggcgcaattt cgcgatttaa acacaaaaat cggcagccgc 1080  
 aaaatcatca accgcaatta tcaattcaat tacggtttat cttaaaactc atatgccaac 1140  
 ctcaatctga ccgcagccta caattccccgc aggcagaaat atccgaaagg gtcgaagttt 1200  
 acaggctggg ggctttaaa agatttgaa acctacaaca acgcgaaaat cctcgacetc 1260  
 aacaacaccg ccaccccccgc gctgccccgc gaaaccgagt tgcaaaccac ttgggcttc 1320  
 aattatttcc acaaacgaata cggcaaaaac cgcttcctg aagaattggg gctgttttc 1380  
 gacggcccg atcaggacaa cgggctttat tcctatttgg ggccggtttaa gggcgataaa 1440  
 gggctgctgc cccaaaaatc aaccatcgcc caaccggccg gcagccaata ttcaacacg 1500  
 ttctacttcg atgcccgcgt caaaaaagac atttacgct taaaactacag caccaatacc 1560  
 gtcggctacc gtttcggcgg cgaatatacg ggcttattacg gctcggatga cgaatttaag 1620  
 cgggcattcg gagaaaaatc gccgacatac aagaaacatt gcaaccagag ctgcggaaatt 1680  
 tatgaacccg tattgaaaaa atacggcaa aagcgcgcac acaaccattc ggtcagcatt 1740  
 agtgcggact tcggcgat tttcatcgcc ttgcggacttccatcgccac acaccgtatg 1800  
 cccaaacatcc aagaaatgtt ttttccaa atcggcgact ccggcggttca caccgcctta 1860  
 aaaccagagc gcgcaaacac ttggcaattt ggcttcaata cctataaaaa aggattgtta 1920  
 aaacaagatg atacattagg attaaaactg gtccggctacc gcagccgcat cgacaactac 1980  
 atccacaacg tttacggaa atgggtggat ttgaacggga atattccgag ctgggtcagc 2040  
 agcaccgggc ttgcctacac catccaacac cgcaatttca aagacaaaatg acacaaacac 2100  
 gttttttagt tggagctgaa ttacgattat gggcggtttt tcaccaacct ttcttacgcc 2160  
 tatcaaaaaa gcacgcaacc gaccaacttc agcgatgcga gcgaatcgcc caacaatgcg 2220  
 tccaaagaag accaactcaa acaaggtt ggggttccgc cctggcgaga 2280  
 gattacggac gtttggaaatg cggtagccgc tggttggca acaaactgac tttggggggc 2340  
 gcgatgcgtt attcggcaaa gagcatccgc gcgcggctg aagaacgcata tatcgacggc 2400  
 accaacgggg gaaataccag caatgtccgg caactggca agcgttccat caaacaacc 2460  
 gaaacccttg cccggccagcc tttgattttt gattttacg ccgttacga ggcgaagaaa 2520  
 aaccttattt tccgcggca agtcaaaaat ctgttcgaca ggcgttataat cgatccgctc 2580  
 gatgcgggca atgatgcggc aacgcagcgt tattacagtt cggtcgaccc gaaagacaag 2640  
 gacgaagaag taacgtgtaa tgctgataaa acgttgtgca acggcaataa cggcggcaca 2700  
 agcaaaaagcg tattgacca ttttgcacgc ggacgcaccc ttttgcataac gatgagctac 2760  
 aagttttaa 2769

<210> 2  
 <211> 922  
 <212> PRT  
 <213> Bacteria

<400> 2  
 Met Arg Ser Ser Phe Arg Leu Lys Pro Ile Cys Phe Tyr Leu Met Gly  
 1 5 10 15  
 Val Met Leu Tyr His His Ser Tyr Ala Glu Asp Ala Gly Arg Ala Gly  
 20 25 30

Ser Glu Ala Gln Ile Gln Val Leu Glu Asp Val His Val Lys Ala Lys  
           35                  40                  45  
 Arg Val Pro Lys Asp Lys Lys Val Phe Thr Asp Ala Arg Ala Val Ser  
       50                  55                  60  
 Thr Arg Gln Asp Ile Phe Lys Ser Ser Glu Asn Leu Asp Asn Ile Val  
       65                  70                  75                  80  
 Arg Ser Ile Pro Gly Ala Phe Thr Gln Gln Asp Lys Ser Ser Gly Ile  
       85                  90                  95  
 Val Ser Leu Asn Ile Arg Gly Asp Ser Gly Phe Gly Arg Val Asn Thr  
       100                 105                 110  
 Met Val Asp Gly Ile Thr Gln Thr Phe Tyr Ser Thr Ser Thr Asp Ala  
       115                 120                 125  
 Gly Arg Ala Gly Gly Ser Ser Gln Phe Gly Ala Ser Val Asp Ser Asn  
       130                 135                 140  
 Phe Ile Ala Gly Leu Asp Val Val Lys Gly Ser Phe Ser Gly Ser Ala  
       145                 150                 155                 160  
 Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val  
       165                 170                 175  
 Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Leu Lys Gly  
       180                 185                 190  
 Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly  
       195                 200                 205  
 Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly  
       210                 215                 220  
 His Ser Arg Arg Thr Trp Ala Gln Asn Tyr Arg Val Gly Gly Gly  
       225                 230                 235                 240  
 Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln  
       245                 250                 255  
 Arg Tyr Phe Val Gln Glu Gly Leu Lys Phe Asn Ser Asn Ser Gly  
       260                 265                 270  
 Lys Trp Glu Arg Asp Phe Gln Arg Pro Tyr Trp Lys Thr Lys Trp Tyr  
       275                 280                 285  
 Gln Lys Tyr Asn Asp Pro Gln Glu Leu Gln Lys Tyr Ile Glu Gly His  
       290                 295                 300  
 Asp Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro  
       305                 310                 315                 320  
 Ile Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys  
       325                 330                 335  
 Leu Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp  
       340                 345                 350  
 Leu Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln

355	360	365
Phe Asn Tyr Gly Leu Ser Leu Asn Ser Tyr Ala Asn Leu Asn Leu Thr		
370	375	380
Ala Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe		
385	390	395
Thr Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys		
405	410	415
Ile Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr		
420	425	430
Glu Leu Gln Thr Thr Leu Gly Phe Asn Tyr Phe His Asn Glu Tyr Gly		
435	440	445
Lys Asn Arg Phe Pro Glu Glu Leu Gly Leu Phe Phe Asp Gly Pro Asp		
450	455	460
Gln Asp Asn Gly Leu Tyr Ser Tyr Leu Gly Arg Phe Lys Gly Asp Lys		
465	470	475
Gly Leu Leu Pro Gln Lys Ser Thr Ile Val Gln Pro Ala Gly Ser Gln		
485	490	495
Tyr Phe Asn Thr Phe Tyr Phe Asp Ala Ala Leu Lys Lys Asp Ile Tyr		
500	505	510
Arg Leu Asn Tyr Ser Thr Asn Thr Val Gly Tyr Arg Phe Gly Gly Glu		
515	520	525
Tyr Thr Gly Tyr Tyr Gly Ser Asp Asp Glu Phe Lys Arg Ala Phe Gly		
530	535	540
Glu Asn Ser Pro Thr Tyr Lys Lys His Cys Asn Gln Ser Cys Gly Ile		
545	550	555
Tyr Glu Pro Val Leu Lys Lys Tyr Gly Lys Lys Arg Ala Asn Asn His		
565	570	575
Ser Val Ser Ile Ser Ala Asp Phe Gly Asp Tyr Phe Met Pro Phe Ala		
580	585	590
Ser Tyr Ser Arg Thr His Arg Met Pro Asn Ile Gln Glu Met Tyr Phe		
595	600	605
Ser Gln Ile Gly Asp Ser Gly Val His Thr Ala Leu Lys Pro Glu Arg		
610	615	620
Ala Asn Thr Trp Gln Phe Gly Phe Asn Thr Tyr Lys Lys Gly Leu Leu		
625	630	635
Lys Gln Asp Asp Thr Leu Gly Leu Lys Leu Val Gly Tyr Arg Ser Arg		
645	650	655
Ile Asp Asn Tyr Ile His Asn Val Tyr Gly Lys Trp Trp Asp Leu Asn		
660	665	670
Gly Asn Ile Pro Ser Trp Val Ser Ser Thr Gly Leu Ala Tyr Thr Ile		
675	680	685

Gln His Arg Asn Phe Lys Asp Lys Val His Lys His Gly Phe Glu Leu  
 690 695 700  
 Glu Leu Asn Tyr Asp Tyr Gly Arg Phe Phe Thr Asn Leu Ser Tyr Ala  
 705 710 715 720  
 Tyr Gln Lys Ser Thr Gln Pro Thr Asn Phe Ser Asp Ala Ser Glu Ser  
 725 730 735  
 Pro Asn Asn Ala Ser Lys Glu Asp Gln Leu Lys Gln Gly Tyr Gly Leu  
 740 745 750  
 Ser Arg Val Ser Ala Leu Pro Arg Asp Tyr Gly Arg Leu Glu Val Gly  
 755 760 765  
 Thr Arg Trp Leu Gly Asn Lys Leu Thr Leu Gly Gly Ala Met Arg Tyr  
 770 775 780  
 Phe Gly Lys Ser Ile Arg Ala Thr Ala Glu Glu Arg Tyr Ile Asp Gly  
 785 790 795 800  
 Thr Asn Gly Gly Asn Thr Ser Asn Val Arg Gln Leu Gly Lys Arg Ser  
 805 810 815  
 Ile Lys Gln Thr Glu Thr Leu Ala Arg Gln Pro Leu Ile Phe Asp Phe  
 820 825 830  
 Tyr Ala Ala Tyr Glu Pro Lys Lys Asn Leu Ile Phe Arg Ala Glu Val  
 835 840 845  
 Lys Asn Leu Phe Asp Arg Arg Tyr Ile Asp Pro Leu Asp Ala Gly Asn  
 850 855 860  
 Asp Ala Ala Thr Gln Arg Tyr Tyr Ser Ser Phe Asp Pro Lys Asp Lys  
 865 870 875 880  
 Asp Glu Glu Val Thr Cys Asn Ala Asp Lys Thr Leu Cys Asn Gly Lys  
 885 890 895  
 Tyr Gly Gly Thr Ser Ser Val Leu Thr Asn Phe Ala Arg Gly Arg  
 900 905 910  
 Thr Phe Leu Ile Thr Met Ser Tyr Lys Phe  
 915 920

<210> 3  
<211> 2769  
<212> DNA  
<213> Bacteria

<400> 3

atgagatctt ctttccgggtt gaagccgatt tggttttatc ttatgggtgt tatgctatat	60
catcatagtt atgccgaaga tgcaggcgcc gcgggcagcg aggcgcagat acaggtttg	120
gaagatgtgc acgtcaaggc gaagcgcgtt ccgaaagaca aaaaagtgtt taccgatgcg	180
cgtgccgtat cgaccggcgtt ggatataattc aaatccagcg aaaacacctcgta caacatcgta	240

cgacgcatcc ccgggtgcgtt tacacagcaa gataaaagct cgggcattgt gtctttgaat 300  
 attcgccgcg acagcgggtt cgggcgggtc aatacgatgg tggacggcat cacgcagacc 360  
 ttttattcga cttctaccga tgcgggcagg gcaggcgggtt catctcaatt cggtcatct 420  
 gtcgacagca attttattgc cggactggat gtcgtcaaag gcagcttcag cggctcggca 480  
 ggcatcaaca gccttgcggg ttccggcaat ctgcggactt taggcgtgga tgacgtcggt 540  
 cagggcaata atacctacgg cctgctgcta aaaggctctga cccggcaccaa ttcaaccaaa 600  
 ggtaatgcga tggcggcgat aggtgcgcgc aaatggctgg aaagcggagc atctgtcggt 660  
 gtgcatttacg ggcacagcag gcgcagcgtg gcgcattt accgcgtggg cggcggcggg 720  
 cagcacatcg gaaattttgg cgccgaatat ctggAACGGC gcaaggcagcg atattttgt 780  
 caagaaggcg gttgaaaatt caattccaac agcggaaaat gggagcggga ttccaaagg 840  
 ccgtactgga aaaccaagtg gtatcaaaaa tacaatgacc cccaaagaact gcaaaaatac 900  
 atcgaaggc atgacaaaaag ctggcgggaa aacctggcgc cgcaatacga catcaccccc 960  
 atcgatccgt ccagcctgaa gcagcgtcg gcaggcaatc tgtttaattt ggaatacgc 1020  
 ggcgtattca ataaatacac ggcgcattt cgcgatattaa acaccaaaaat cggcagccgc 1080  
 aaaatcatca accgcaatta tcaattcaat tacggtttat ctttaactc atatgccaac 1140  
 ctcaatctga ccgcagccta caattcggc aggccagaat atccgaaagg gtcgaagttt 1200  
 acaggctggg ggctttaaa agattttgaa acctacaaca acgcgaaaat cctcgacctc 1260  
 aacaacacccg ccacccctccg gctgccccgc gaaaccgagt tgcaaaccac ttgggcttc 1320  
 aattatttcc acaacgaata cggcaaaaac cgctttcctg aagaattttgg gctgttttc 1380  
 gacggtccgg atcaggacaa cgggctttat tcctatttgg ggcggttttaa gggcgataaaa 1440  
 gggctgctgc cccaaaaatc aaccatcgcc caacccggccg gcagccaata ttcaacacg 1500  
 ttctacttcg atgcccgcgt caaaaaagac atttaccgt taaaactacag caccataacc 1560  
 gtcggctacc gtttcggcgg cgaatatacg ggctattacg gctcgatga cgaatttaag 1620  
 cggccattcg gagaaaaactc gcccacatac aagaaacatt gcaaccagag ctggaaatt 1680  
 tatgaacccg tattgaaaaa atacggcaaa aagcgcgcac acaaccattc ggtcagcatt 1740  
 agtgcggact tcggcgatta tttcatccg ttcgcctactt attcgcgcac acaccgtatg 1800  
 cccaaatcc aagaaatgtt ttttcccaat atcggcgact ccggcgatca caccgcctt 1860  
 aaaccagagc gcgcaaacac ttggcaattt ggcttcaata cctataaaaa aggattgtt 1920  
 aaacaagatg atacattagg attaaaaactg gtcggctacc gcagccgcac cgacaactac 1980  
 atccacaacg tttacgggaa atggggat ttgaacgggaa atattccag ctgggtcagc 2040  
 agcaccgggc ttgcctacac catccaaacac cgcaatttca aagacaaagt acacaaacac 2100  
 ggttttagt tggagctgaa ttacgattat gggcggtttt tcaccaacct ttcttacgcc 2160  
 tatcaaaaaa gcacgcaacc gaccaacttc agcgatgcga gcgaatcgcc caacaatgcg 2220  
 tccaaagaag accaactcaa acaaggttat gggttgagca gggttccgc cctggcgcga 2280  
 gattacggac gtttggaaagt cggtacgcgc tggttggca acaaaactgac tttggcggc 2340  
 gcgatgcgtt atttcggcaa gagcatccgc gcgcacggctg aagaacgcata tatcgacggc 2400  
 accaacgggg gaaataccag caatgtccgg caactgggca agcgatccat caacaaacc 2460  
 gaaacccttg cccgcccggcc tttgattttt gattttacg ccgcttacga gccgaagaaa 2520  
 aacccatttt tccgcgcga agtcaaaaat ctgttcgaca ggcgttataat cgatccgc 2580  
 gatgcggcga atgatgcggc aacgcagcgt tattacagtt cgttcgaccc gaaagacaag 2640  
 gacgaagaag taacgtgtaa tgctgataaa acgttgtgca acggcaataa cggcggcaca 2700

agcaaaaagcg tattgaccaa ttttgcacgc ggacgcacct ttttgataac gatgagctac	2760
aagttaaa	2769

<210> 4  
<211> 922  
<212> PRT  
<213> Bacteria

<400> 4		
Met Arg Ser Ser Phe Arg Leu Lys Pro Ile Cys Phe Tyr Leu Met Gly		
1	5	10
Val Met Leu Tyr His His Ser Tyr Ala Glu Asp Ala Gly Arg Ala Gly		
20	25	30
Ser Glu Ala Gln Ile Gln Val Leu Glu Asp Val His Val Lys Ala Lys		
35	40	45
Arg Val Pro Lys Asp Lys Lys Val Phe Thr Asp Ala Arg Ala Val Ser		
50	55	60
Thr Arg Gln Asp Ile Phe Lys Ser Ser Glu Asn Leu Asp Asn Ile Val		
65	70	75
Arg Ser Ile Pro Gly Ala Phe Thr Gln Gln Asp Lys Ser Ser Gly Ile		
85	90	95
Val Ser Leu Asn Ile Arg Gly Asp Ser Gly Phe Gly Arg Val Asn Thr		
100	105	110
Met Val Asp Gly Ile Thr Gln Thr Phe Tyr Ser Thr Ser Thr Asp Ala		
115	120	125
Gly Arg Ala Gly Gly Ser Ser Gln Phe Gly Ala Ser Val Asp Ser Asn		
130	135	140
Phe Ile Ala Gly Leu Asp Val Val Lys Gly Ser Phe Ser Gly Ser Ala		
145	150	155
Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val		
165	170	175
Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Leu Lys Gly		
180	185	190
Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly		
195	200	205
Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly		
210	215	220
His Ser Arg Arg Ser Val Ala Gln Asn Tyr Arg Val Gly Gly Gly		
225	230	235
Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln		
245	250	255

Arg Tyr Phe Val Gln Glu Gly Gly Leu Lys Phe Asn Ser Asn Ser Gly  
                  260                 265                 270  
 Lys Trp Glu Arg Asp Phe Gln Arg Pro Tyr Trp Lys Thr Lys Trp Tyr  
                  275                 280                 285  
 Gln Lys Tyr Asn Asp Pro Gln Glu Leu Gln Lys Tyr Ile Glu Gly His  
                  290                 295                 300  
 Asp Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro  
                  305                 310                 315                 320  
 Ile Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys  
                  325                 330                 335  
 Leu Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp  
                  340                 345                 350  
 Leu Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln  
                  355                 360                 365  
 Phe Asn Tyr Gly Leu Ser Leu Asn Ser Tyr Ala Asn Leu Asn Leu Thr  
                  370                 375                 380  
 Ala Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe  
                  385                 390                 395                 400  
 Thr Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys  
                  405                 410                 415  
 Ile Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr  
                  420                 425                 430  
 Glu Leu Gln Thr Thr Leu Gly Phe Asn Tyr Phe His Asn Glu Tyr Gly  
                  435                 440                 445  
 Lys Asn Arg Phe Pro Glu Glu Leu Gly Leu Phe Phe Asp Gly Pro Asp  
                  450                 455                 460  
 Gln Asp Asn Gly Leu Tyr Ser Tyr Leu Gly Arg Phe Lys Gly Asp Lys  
                  465                 470                 475                 480  
 Gly Leu Leu Pro Gln Lys Ser Thr Ile Val Gln Pro Ala Gly Ser Gln  
                  485                 490                 495  
 Tyr Phe Asn Thr Phe Tyr Phe Asp Ala Ala Leu Lys Lys Asp Ile Tyr  
                  500                 505                 510  
 Arg Leu Asn Tyr Ser Thr Asn Thr Val Gly Tyr Arg Phe Gly Gly Glu  
                  515                 520                 525  
 Tyr Thr Gly Tyr Tyr Gly Ser Asp Asp Glu Phe Lys Arg Ala Phe Gly  
                  530                 535                 540  
 Glu Asn Ser Pro Thr Tyr Lys Lys His Cys Asn Gln Ser Cys Gly Ile  
                  545                 550                 555                 560  
 Tyr Glu Pro Val Leu Lys Lys Tyr Gly Lys Lys Arg Ala Asn Asn His  
                  565                 570                 575  
 Ser Val Ser Ile Ser Ala Asp Phe Gly Asp Tyr Phe Met Pro Phe Ala

580	585	590
Ser Tyr Ser Arg Thr His Arg Met Pro Asn Ile Gln Glu Met Tyr Phe		
595	600	605
Ser Gln Ile Gly Asp Ser Gly Val His Thr Ala Leu Lys Pro Glu Arg		
610	615	620
Ala Asn Thr Trp Gln Phe Gly Phe Asn Thr Tyr Lys Lys Gly Leu Leu		
625	630	635
Lys Gln Asp Asp Thr Leu Gly Leu Lys Leu Val Gly Tyr Arg Ser Arg		
645	650	655
Ile Asp Asn Tyr Ile His Asn Val Tyr Gly Lys Trp Trp Asp Leu Asn		
660	665	670
Gly Asn Ile Pro Ser Trp Val Ser Ser Thr Gly Leu Ala Tyr Thr Ile		
675	680	685
Gln His Arg Asn Phe Lys Asp Lys Val His Lys His Gly Phe Glu Leu		
690	695	700
Glu Leu Asn Tyr Asp Tyr Gly Arg Phe Phe Thr Asn Leu Ser Tyr Ala		
705	710	715
Tyr Gln Lys Ser Thr Gln Pro Thr Asn Phe Ser Asp Ala Ser Glu Ser		
725	730	735
Pro Asn Asn Ala Ser Lys Glu Asp Gln Leu Lys Gln Gly Tyr Gly Leu		
740	745	750
Ser Arg Val Ser Ala Leu Pro Arg Asp Tyr Gly Arg Leu Glu Val Gly		
755	760	765
Thr Arg Trp Leu Gly Asn Lys Leu Thr Leu Gly Gly Ala Met Arg Tyr		
770	775	780
Phe Gly Lys Ser Ile Arg Ala Thr Ala Glu Glu Arg Tyr Ile Asp Gly		
785	790	795
Thr Asn Gly Gly Asn Thr Ser Asn Val Arg Gln Leu Gly Lys Arg Ser		
805	810	815
Ile Lys Gln Thr Glu Thr Leu Ala Arg Gln Pro Leu Ile Phe Asp Phe		
820	825	830
Tyr Ala Ala Tyr Glu Pro Lys Lys Asn Leu Ile Phe Arg Ala Glu Val		
835	840	845
Lys Asn Leu Phe Asp Arg Arg Tyr Ile Asp Pro Leu Asp Ala Gly Asn		
850	855	860
Asp Ala Ala Thr Gln Arg Tyr Tyr Ser Ser Phe Asp Pro Lys Asp Lys		
865	870	875
Asp Glu Glu Val Thr Cys Asn Ala Asp Lys Thr Leu Cys Asn Gly Lys		
885	890	895
Tyr Gly Gly Thr Ser Lys Ser Val Leu Thr Asn Phe Ala Arg Gly Arg		
900	905	910

Thr Phe Leu Ile Thr Met Ser Tyr Lys Phe

915

920

<210> 5

<211> 2766

<212> DNA

<213> Bacteria

<400> 5

atgagatctt	ctttccgggtt	gaagccgatt	tgttttacc	ttatgggtgt	tacgctatat	60
cattatagtt	atgccgaaga	tgcagggcgc	gcgggcagcg	aggcgcatat	acagggtttg	120
gaagatgtgc	acgtcaaggc	gaagcgcgt	ccgaaagaca	aaaaagtgtt	taccgatgcg	180
cgtgcgtat	cgaccgtca	ggatataattc	aaatccagcg	aaaacctcg	caacatcgta	240
cgcagcatcc	ccgggtgcgtt	tacacagcaa	gataaaagct	cgggcattgt	gtcttgaat	300
attcgcggcg	acagcgggtt	cgggcgggtc	aatacgatgg	tggacggcat	cacgcagacc	360
ttttatttcga	cttctaccga	tgcgggcagg	gcaggcgggtt	catctcaatt	cggtgcattct	420
gtcgacagca	attttattgc	cggactggat	gtcgtaaaag	gcagcttcag	cggctcggca	480
ggcatcaaca	gccttgccgg	ttcggcgaat	ctgcccatt	taggcgtgga	tgacgtcggt	540
cagggcaata	atacctacgg	cctgctcta	aaaggtctga	cgggcaccaa	ttcaacccaaa	600
ggtaatgcga	tggcggcgat	aggtgcgcgc	aaatggctgg	aaagcggagc	atctgtcggt	660
gtgcttacg	ggcacacgc	gcmcagcgt	gcgcacaaatt	accgcgtggg	cgccggcggg	720
cagcacatcg	gaaaattttgg	cgcggaatat	ttggAACGGC	gcaagcagcg	atattttgt	780
caagagggtg	cttgcacaaatt	caattccgac	agcgaaaaat	gggagcggga	tttacaagg	840
caacagtgg	aataacaagcc	gtataaaaaat	tacaacaacc	aagaactaca	aaaatacatc	900
gaaggtcatg	acaaaagctg	gcgggaaaaac	ctggcgccgc	aatacgacat	caccccatc	960
gatccgtcca	gcctgaagca	gcagtccgca	ggcaatctgt	ttaaatttgg	atacgacggc	1020
gtattcaata	aatacacggc	gcaatttcgc	gatTTAAACA	ccaaaatcg	cagccgcaaa	1080
atcatcaacc	gcaatttatca	gttcaattac	ggtttgcctt	tgaacccgta	taccaacctc	1140
aatctgaccg	cagcctacaa	ttcgggcagg	cagaatatac	cgaaagggtc	gaagtttaca	1200
ggctgggggc	ttttaaagg	tttgcacaa	tacaacaacg	cgaaaatcct	cgacctcaac	1260
aacaccgcca	ccttccggct	gccccgcgaa	accgagttgc	aaaccacttt	gggcttcaat	1320
tatTTCCACA	acgaatacgg	caaaaaaccgc	tttgcacaa	aattggggct	gttttgcac	1380
ggtcctgatc	aggacaacgg	gttttattcc	tatttggggc	ggtttaagg	cgataaagg	1440
ctgctcccc	aaaaatcaac	cattgtccaa	ccggccggca	gccaatattt	caacacgttc	1500
tacttcgatc	ccgcgcgtca	aaaagacatt	taccgctta	actacagcac	caataccgtc	1560
ggctaccgtt	tccggccgc	atatacgggc	tattacggct	cgatgcga	atTTAAGCGG	1620
gcatttcggag	aaaaactcgcc	gacatacaag	aaacattgc	accggagctg	cgggatttat	1680
gaaccctgtat	tgaaaaaaaata	cgccaaaaag	cgcgcacaca	accattcggt	cagcattagt	1740
gcggacttcg	gcgattattt	catgcgttc	gccagctatt	cgcgacacaca	ccgtatgccc	1800
aacatccaag	aaatgttattt	ttcccaatac	ggcactccg	gcgttcacac	cgcctaaaaa	1860
ccagagcgcg	caaacaacttg	gcaatttggc	ttcaataac	ataaaaaagg	attgtaaaaa	1920

caagatgata cattaggatt aaaactggtc ggctaccgca gccgcacatcgca caactacatc 1980  
 cacaacgttt acggggaaatg gtgggatttg aacggggata ttccgagctg ggtcagcagc 2040  
 accggggcttg cctacaccat ccaacatcgca aatttcaaag acaaagtgcacaaacacgg 2100  
 tttgagttgg agctgaatta cgattatggg cgtttttca ccaaccttgc ttacgcctat 2160  
 caaaaaaaaaagca cgcaaccgac caacttcagc gatgcgagcg aatgcggccaa caatgcgtcc 2220  
 aaagaagacc aactcaaaca aggttatggg ttgagcaggg ttccgcgcct gccgcgagat 2280  
 tacggacgtt tggaaagtgg tacgcgtgg ttgggcaaca aactgacttt gggcggcgcg 2340  
 atgcgctatt tcggcaagag catccgcgcg acggctgaag aacgctatat cgacggcacc 2400  
 aacgggggaa ataccagcaa tttccggcaa ctgggcaagc gttccatcaa acaaaccgaa 2460  
 actcttgcgc gccagccctt gattttgtt ttacgcgcg cttacgagcc gaagaaaaac 2520  
 cttatccc ggcggcaagt caaaaaaaaatctg ttgcacagggc gtttatatcga tccgctcgat 2580  
 gcgggcaatg atgcggcaac gcagcggtt tacagctcgat tcgacccgaa agacaaggac 2640  
 gaagacgtaa cgtgtaatgc tgataaaaacg ttgtgcaacg gcaaatacgg cggcacaaggc 2700  
 aaaagcgtat tgaccaattt tgacgcggc cgcaccttt tgataacgat gagctacaag 2760  
 ttttaa 2766

&lt;210&gt; 6

&lt;211&gt; 921

&lt;212&gt; PRT

&lt;213&gt; Bacteria

&lt;400&gt; 6

Met	Arg	Ser	Ser	Phe	Arg	Leu	Lys	Pro	Ile	Cys	Phe	Tyr	Leu	Met	Gly
1								10						15	
Val	Thr	Leu	Tyr	His	Tyr	Ser	Tyr	Ala	Glu	Asp	Ala	Gly	Arg	Ala	Gly
								20		25			30		
Ser	Glu	Ala	Gln	Ile	Gln	Val	Leu	Glu	Asp	Val	His	Val	Lys	Ala	Lys
								35		40			45		
Arg	Val	Pro	Lys	Asp	Lys	Val	Phe	Thr	Asp	Ala	Arg	Ala	Val	Ser	
								50		55			60		
Thr	Arg	Gln	Asp	Ile	Phe	Lys	Ser	Ser	Glu	Asn	Leu	Asp	Asn	Ile	Val
								65		70			75		80
Arg	Ser	Ile	Pro	Gly	Ala	Phe	Thr	Gln	Gln	Asp	Lys	Ser	Ser	Gly	Ile
								85		90			95		
Val	Ser	Leu	Asn	Ile	Arg	Gly	Asp	Ser	Gly	Phe	Gly	Arg	Val	Asn	Thr
								100		105			110		
Met	Val	Asp	Gly	Ile	Thr	Gln	Thr	Phe	Tyr	Ser	Thr	Ser	Thr	Asp	Ala
								115		120			125		
Gly	Arg	Ala	Gly	Gly	Ser	Ser	Gln	Phe	Gly	Ala	Ser	Val	Asp	Ser	Asn
								130		135			140		
Phe	Ile	Ala	Gly	Leu	Asp	Val	Val	Lys	Gly	Ser	Phe	Ser	Gly	Ser	Ala

145	150	155	160
Gly Ile Asn Ser Leu Ala Gly Ser Ala Asn Leu Arg Thr Leu Gly Val			
165	170	175	
Asp Asp Val Val Gln Gly Asn Asn Thr Tyr Gly Leu Leu Lys Gly			
180	185	190	
Leu Thr Gly Thr Asn Ser Thr Lys Gly Asn Ala Met Ala Ala Ile Gly			
195	200	205	
Ala Arg Lys Trp Leu Glu Ser Gly Ala Ser Val Gly Val Leu Tyr Gly			
210	215	220	
His Ser Arg Arg Ser Val Ala Gln Asn Tyr Arg Val Gly Gly Gly			
225	230	235	240
Gln His Ile Gly Asn Phe Gly Ala Glu Tyr Leu Glu Arg Arg Lys Gln			
245	250	255	
Arg Tyr Phe Val Gln Glu Gly Ala Leu Lys Phe Asn Ser Asp Ser Gly			
260	265	270	
Lys Trp Glu Arg Asp Leu Gln Arg Gln Trp Lys Tyr Lys Pro Tyr			
275	280	285	
Lys Asn Tyr Asn Asn Gln Glu Leu Gln Lys Tyr Ile Glu Gly His Asp			
290	295	300	
Lys Ser Trp Arg Glu Asn Leu Ala Pro Gln Tyr Asp Ile Thr Pro Ile			
305	310	315	320
Asp Pro Ser Ser Leu Lys Gln Gln Ser Ala Gly Asn Leu Phe Lys Leu			
325	330	335	
Glu Tyr Asp Gly Val Phe Asn Lys Tyr Thr Ala Gln Phe Arg Asp Leu			
340	345	350	
Asn Thr Lys Ile Gly Ser Arg Lys Ile Ile Asn Arg Asn Tyr Gln Phe			
355	360	365	
Asn Tyr Gly Leu Ser Leu Asn Pro Tyr Thr Asn Leu Asn Leu Thr Ala			
370	375	380	
Ala Tyr Asn Ser Gly Arg Gln Lys Tyr Pro Lys Gly Ser Lys Phe Thr			
385	390	395	400
Gly Trp Gly Leu Leu Lys Asp Phe Glu Thr Tyr Asn Asn Ala Lys Ile			
405	410	415	
Leu Asp Leu Asn Asn Thr Ala Thr Phe Arg Leu Pro Arg Glu Thr Glu			
420	425	430	
Leu Gln Thr Thr Leu Gly Phe Asn Tyr Phe His Asn Glu Tyr Gly Lys			
435	440	445	
Asn Arg Phe Pro Glu Glu Leu Gly Leu Phe Phe Asp Gly Pro Asp Gln			
450	455	460	
Asp Asn Gly Leu Tyr Ser Tyr Leu Gly Arg Phe Lys Gly Asp Lys Gly			
465	470	475	480

Leu Leu Pro Gln Lys Ser Thr Ile Val Gln Pro Ala Gly Ser Gln Tyr  
                  485                        490                        495  
 Phe Asn Thr Phe Tyr Phe Asp Ala Ala Leu Lys Lys Asp Ile Tyr Arg  
                  500                        505                        510  
 Leu Asn Tyr Ser Thr Asn Thr Val Gly Tyr Arg Phe Gly Gly Glu Tyr  
                  515                        520                        525  
 Thr Gly Tyr Tyr Gly Ser Asp Asp Glu Phe Lys Arg Ala Phe Gly Glu  
                  530                        535                        540  
 Asn Ser Pro Thr Tyr Lys Lys His Cys Asn Arg Ser Cys Gly Ile Tyr  
                  545                        550                        555                        560  
 Glu Pro Val Leu Lys Lys Tyr Gly Lys Lys Arg Ala Asn Asn His Ser  
                  565                        570                        575  
 Val Ser Ile Ser Ala Asp Phe Gly Asp Tyr Phe Met Pro Phe Ala Ser  
                  580                        585                        590  
 Tyr Ser Arg Thr His Arg Met Pro Asn Ile Gln Glu Met Tyr Phe Ser  
                  595                        600                        605  
 Gln Ile Gly Asp Ser Gly Val His Thr Ala Leu Lys Pro Glu Arg Ala  
                  610                        615                        620  
 Asn Thr Trp Gln Phe Gly Phe Asn Thr Tyr Lys Lys Gly Leu Leu Lys  
                  625                        630                        635                        640  
 Gln Asp Asp Thr Leu Gly Leu Lys Leu Val Gly Tyr Arg Ser Arg Ile  
                  645                        650                        655  
 Asp Asn Tyr Ile His Asn Val Tyr Gly Lys Trp Trp Asp Leu Asn Gly  
                  660                        665                        670  
 Asp Ile Pro Ser Trp Val Ser Ser Thr Gly Leu Ala Tyr Thr Ile Gln  
                  675                        680                        685  
 His Arg Asn Phe Lys Asp Lys Val His Lys His Gly Phe Glu Leu Glu  
                  690                        695                        700  
 Leu Asn Tyr Asp Tyr Gly Arg Phe Phe Thr Asn Leu Ser Tyr Ala Tyr  
                  705                        710                        715                        720  
 Gln Lys Ser Thr Gln Pro Thr Asn Phe Ser Asp Ala Ser Glu Ser Pro  
                  725                        730                        735  
 Asn Asn Ala Ser Lys Glu Asp Gln Leu Lys Gln Gly Tyr Gly Leu Ser  
                  740                        745                        750  
 Arg Val Ser Ala Leu Pro Arg Asp Tyr Gly Arg Leu Glu Val Gly Thr  
                  755                        760                        765  
 Arg Trp Leu Gly Asn Lys Leu Thr Leu Gly Gly Ala Met Arg Tyr Phe  
                  770                        775                        780  
 Gly Lys Ser Ile Arg Ala Thr Ala Glu Glu Arg Tyr Ile Asp Gly Thr  
                  785                        790                        795                        800  
 Asn Gly Gly Asn Thr Ser Asn Phe Arg Gln Leu Gly Lys Arg Ser Ile

805                    810                    815  
Lys Gln Thr Glu Thr Leu Ala Arg Gln Pro Leu Ile Phe Asp Phe Tyr  
820                    825                    830  
Ala Ala Tyr Glu Pro Lys Lys Asn Leu Ile Phe Arg Ala Glu Val Lys  
835                    840                    845  
Asn Leu Phe Asp Arg Arg Tyr Ile Asp Pro Leu Asp Ala Gly Asn Asp  
850                    855                    860  
Ala Ala Thr Gln Arg Tyr Tyr Ser Ser Phe Asp Pro Lys Asp Lys Asp  
865                    870                    875                    880  
Glu Asp Val Thr Cys Asn Ala Asp Lys Thr Leu Cys Asn Gly Lys Tyr  
885                    890                    895  
Gly Gly Thr Ser Lys Ser Val Leu Thr Asn Phe Ala Arg Gly Arg Thr  
900                    905                    910  
Phe Leu Ile Thr Met Ser Tyr Lys Phe  
915                    920

<210> 7  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 7

gcttagctgc agatcttctt tcgggaagaa                    30

<210> 8  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 8

ggtcgctcga gaaaacttgta gctcatcggt atca                    34

<210> 9  
<211> 1000  
<212> DNA

&lt;213&gt; Bacteria

&lt;400&gt; 9

tatccgataa gtttccgtac cgaacagact agattccccgc ctgcgcggga atgacgattc	60
ataagttcc cgaaattcca acataaccga aacctgacag taaccgttagc aactgaaccg	120
tcattcccac gaaaagtggga atctagaaaat gaaaagcaac aggcatatcg cggaaataac	180
tgaaaacogaa cagacttagat tcccgcctgc gcgggaatga cgattcataa gtttccgaa	240
attccaaacat aaccgaaacc tgacagtaac cgttagtaact gaaccgtcat tcccacgaaa	300
gtgggaatct agaaaatgaaa agcaacaggc atttatcgga aataactgga accgaacaga	360
cctagattcc cgcctgcgcgc ggaatgacgg ctgcagatgc ccgcacggct ttatagcaga	420
ttaacaaaaa tcaggacaag gcggcgagcc acagacagta caaacagtagc ggaaccgatt	480
cacttggtgc ttcagcacct tagagaatcg ttctcttga gctaaggcga gacaacgcgc	540
tactggttt tgtaatccg ctatattccg ccatctctaa gatttacagc gatacacggg	600
taatttaagg aatggccgaa ccgtcattcc cgccactttt cgtcattccc accactttc	660
gtcattcccgc cgcaggcggg aatctagaat ctggacttt cagataatct ttgaatattg	720
ctgttgttct aaggttttaga ttccccttgc gcgggaatga cgattcataa gtttccgaa	780
attccaaacat aaccgaaacc tgacagtaac cgtagcaaca gagaatcggt ctcttgagc	840
taaggcgaaa caacgctgta ccggttttt ttaatccact ataaaatatcc aattgaaatc	900
ttcagacggt atatcgatt tacactttt aatgtttatg ccgcctaaaa aaatgctaatt	960
atatttctta attgtctgac tgtttattgt tgaggaaaat	1000

**SEQUENCE INFORMATION****BASB024 Polynucleotide and Polypeptide Sequences****SEQ ID NO:1*****Neisseria meningitidis* BASB024 polynucleotide sequence from strain ATCC 13090**

ATGAGATCTTCTTCGGTTGAAGCCGATTGTTTATCTTATGGGTGTTATGCTATATCATCATAGTTATGCCGAAGA  
TGCAGGGCGCGCGGGCAGCGAGGCGCAGATAACAGGTTTGGAAAGATGTGCACGTCAAGGCGAAGCGCGTACCGAAAGACA  
AAAAAGTGTACCGATGCGCGTGCCTATCGACCCGTAGGATATATTCAAATCCAGCGAAAACCTCGACAAACATCGTA  
CGCAGCATCCCCGGTGCCTTACACAGCAAGATAAAAGCTCGGGCATTGTGTCCTTGAATATTGCGGGCACAGCGGGTT  
CGGGCGGGTCAATACGATGGTGGACGGCATCACGCAGACCTTTATTGACTTCTACCGATGCGGGCAGGGCAGGCAGGTT  
CATCTCAATTGGTGCATCTGTCAGCAAGCAATTATTGCGGACTGGATGTCGTCAAAGGCAGCTTCAGCGCTCGGCA  
GGCATCAACAGCCTTGCCGGTTCGGCGAATCTGGACTTTAGGCGTGGATGACGTGTTCAAGGCAATAATACCTACGG  
CCTGCTGCTAAAAGGTCTGACCGGCACCAATTCAACCAAAGGTAAATGCGATGGCGCGTAGGTGCGCAGGCAAATGGCTGG  
AAAGCGGAGCATCTGCGGTGCTTACGGCACAGCAGGCGCACGTGGCGCAAAATTACCGCGTGGCGGCGAGGCGGGTTGAAATT  
CAGCACATCGGAAATTGGCGGGAATATCTGGACGGCGAAACAGCGATATTGTACAAGAAGGCGGGTTGAAATT  
CAATTCCAACAGCGGAAATGGGAGCGGGATTICCAAGGCCGTACTGGAAACCAAGTGGTATCAAAAATACAATGACC  
CCCAAGAACTGCAAAATACATCGAAGGTCACTGACAAAAGCTGGCGGGAAACCTGGCGCCCAATACGACATCACCCCC  
ATCGATCCGTCCAGCCTGAAGCAGCAGTCGGCAGGCAATCTGTTAAATTGGAATACGACGGGTATTCAATAATACAC  
GGCGCAATTGCGATTAAACACCAAAATCGCAGCGCAAAATCATCAACCGCAATTATCAATTCAATTACGGTTTAT  
CTTTAAACTCATATGCCAACCTCAATCTGACCGCAGCCTACAATTGGCAGGAGAAATATCGAAAGGGTCAAGTT  
ACAGGCTGGGGCTTTAAAAGATTGAAACCTACAACACCGGAAACCTCAACACCGCCACCTTCG  
GCTGCCCGCAGGTTGCAAACCAACTTGGCTTCATTATTCCACAAAGAATACGGCAAAACCGCTTCTG  
AAGAATTGGGCTGTTTCGACGGTCCGGATCAGGACAACGGGTTTATTCTATTGGCGGTTAAGGGCGATAAA  
GGGCTGCTGCCCAAAATCAACCATCGTCCAACCGGCCGGCAGCCAATATTCAACAGTCTACTTCGATGCCGCGCT  
CAAAAAGACATTACCGTTAAACTACAGCACCAATACCGTGGCTACCGTTTCGGCGGAATATACGGCTATTACG  
GCTCGGATGACGAATTAAAGCGGGATTCCGGAGAAAATCGCCGACATACAAGAAACATTGCAACCAGAGCTGCCGAATT  
TATGAACCCGTATTGAAAAAAATACGGCAAAAGCGGCCAACACCATTGGTCAAGCATTAGTGGACTTCGGCGATTA  
TTTCATGCCGTTGCCAGCTATTGCGCACACACCGTATGCCAACATCCAAGAAATGTATTTCACCGTTACGGCTATTACG  
CCGGCGTTCACACCGCTTAAACACAGAGCGCGAACACTGGCAATTGGCTCAATACCTATAAAAAGGATTGTTA  
AAACAAGATGATACTATTAGGATTTAAACTGGTGGCTACCGCAGCCGATCGACAACATCCACACCGTTACGGAA  
ATGGTGGGATTGAAACGGGAATTCCGAGCTGGCTAGCAGCAGCACCCGGCTTGGCTACACCATCCAACACCGCAATTCA  
AAGACAAAGTACACAAACACGGTTTGAGTTGGAGCTGAATTACGATTATGGCGTTTTCACCAACCTTCTTACGCC  
TATCAAAAAGCAGCAACCGACCAACTTCAGCGATGCCGAGCGAATGCCAACATGCGTCAAAGAAGACCAACTCAA  
ACAAGGTTATGGGTTGAGCAGGGTTCCGCCCTGCCGAGATTACGGACGTTGGAAAGTCGGTACGCCGCTGGTGGCA  
ACAAACTGACTTTGGCGGCCGATGCGTATTTCGGCAAGAGCATCCGCCGACGGCTGAAGAACGCTATATCGACGGC  
ACCAACGGGGAAATACCAAGCAATGTCGCCAATGGCAAGCGTCCATCAAACAAACCGAAACCCCTGCCAGCC  
TTTGATTTGATTTTACGCCGTTACGAGCCGAAGAAAAACCTTATTTCGGCGCCGAAGTCAAAATCTGTTGACA

GGCGTTATATCGATCCGCTCGATGCCGGCAATGATGCCGGCACGCAGCGTTATTACAGTTCGTCAACCCGAAAGACAAG  
GACGAAGAAGTAACGTGAATGCTGATAAAACGTTGTCAACGGCAAATACGGCGCACAGCAAAAGCGTATTGACCAA  
TTTGCACGCCGACGCCACCTTTGATAACGATGAGCTACAAGTTAA

### SEQ ID NO:2

*Neisseria meningitidis* BASB024 polypeptide sequence deduced from the polynucleotide of SeQ ID NO:1

MRSSFRLKPICFYLMGVMLYHHSYAEDAGRAGSEAQIQVLEDVHVAKRVPDKKVFTDARAVSTRQDIFKSSENLDNIV  
RSIPGAFTQQDKSSGIVSLNIRGDGFGRVNTMDGITQTFYSTSTDAGRAGGSSQFGASVDSNFIAGLDVVKGSFSGSA  
GINSLAGSANLRTLGVDDVVQGNNTYGLLLKGLTGTNSTKGNAMEAIGARKWLES GASVGVLVGHSSRTWAQNYRVGGGG  
QHIGNFGAEYLERRKQRYFVQEGLKFNSNSGWERDFQRPYWKTKWYQKYNDPQELQKYIEGHDKSWRENLAPOYDITP  
IDPSSLKQQSAGNLKLEYDGVFNKYTAQFRDLNTKIGSRKIINRNYQFNYGLS LNSYANLNLTAAYNNSGRQKYPKGSKF  
TGWGLLKDFTETYNNAKILDLNNTATFRLPRETELQTTLGPNYFHNEYGKNRFPEELGLFFDGPQDNGLYSYLGRFKGDK  
GLLPQKSTIVQPAGSQYFNTFYFDAALKDIYRLNYSNTVGYRGEGEYTGYYGSDDFKRAFGENSPTYKKHCNQSCGI  
YEPVLUKKYGKKRANNHSVSISADFGDYFMPFASYSRTHRMPNIQEMYFSQIGDSGVHTALKPERANTWQFGFNTYKKGLL  
KQDDTLGLKLVGYRSRIDNYIHNVYKWWDLNGNIPSWSSTGLAYTIQHRNFKDVKHKHGFELNYDYGRFFTNLSYA  
YQKSTQPTNFSDASESPNNASKEDQLKQGYGLSRVSALPRDYGRLEVGTRWLGNKLTGGMARYFGKSIRATAEERYIDG  
TNGGNTSNVRQLGKRSIKQTETLARQPLIFDFYAAYPEKKNLIFRAEVKNLFDRRYIDPLDAGNDAATQRYYSSFDPKDK  
DEEVTCNADKTLNCNGKYGGTSKSVLTNFARGRTFLITMSYKF

### SEQ ID NO:3

*Neisseria meningitidis* BASB024 polynucleotide sequence from strain ATCC 13090

ATGAGATCTTCTTCCGGTTGAAGCCGATTGTTTTATCTTATGGGTGTTATGCTATATCATCATAGTTATGCCGAAGA  
TGCAGGGCGCGCGGGCAGCGAGGCGCAGATAACAGGTTTGGAAAGATGTGACGTCAAGGCGAACGCGTACCGAAAGACA  
AAAAAGTGTACCGATGCGCGTCCGTATCGACCCGTCAAGGATATATTCAAATCCAGCGAAACCTCGACAACATCGTA  
CGCAGCATCCCCGGTGCCTTACACAGCAAGATAAAAGCTCGGCATTGTCTTGAATATTGCGGGCACAGCGGGTT  
CGGGCGGGTCAATACGATGGGGACGGCATCACGCAGACCTTTATTGCACTTCTACCGATGCGGGCAGGGCAGGCGGTT  
CATCTCAATTGGTGCATCTGTCGACAGCAATTATTGCGGACTGGATGTGTCAAAGGCAGCTTCAGCGGCTCGGCA  
GGCATCAACAGCCTTGCCTCGCGAATCTGCGGACTTTAGGCGGGATGACGTGTTCAAGGCAATAATACCTACGG  
CCTGCTGCTAAAGGTCTGACCGGCCACCAATTCAACCAAAGGTAATGCGATGGCGCGATAGGTGCGCGCAAATGGCTGG  
AAAGCGGAGCATCTGCGGTGCTTACGGCACAGCAGGCGCAGctGGCGCAAATTACCGCGTGGCGCGCGGG  
CAGCACATCGGAAATTGGCGCGGAATATCTGGAACGGCGAAgCAGCGATATTGTACAAGAAGGCGGGTTGAAATT  
CAATTCCAACAGCGGAAATGGGAGCGGGATTCCAAGGCCGTACTGGAAAACCAAGTGGTATCAAAAATACAATGACC  
CCCAGAACTGCAAAATACATCGAAGGTATGACAAAGCTGGCGGGAAACCTGGCGCCCAATACGACATCACCCCC  
ATCGATCCGTCCAGCCTGAAGCAGCAGTCGGCAGGCAATCTGTTAAATTGGAATACGACGGCGTATTCAATAAATACAC  
GGCGCAATTGCGATTAAACACCAAAATCGCAGCCGAAAATCATCAACCGCAATTCAATTCAATTACGGTTAT  
CTTAAACTCATATGCCAACCTCAATCTGACCGCAGCCTACAATTGGGCAGGCAGAAATATCCGAAAGGGTCGAAGTT

ACAGGGCTGGGGCTTTAAAAGATTTGAAACCTACAACAACGCGAAAATCCTCGACCTCAACAACACGCCACCTCCG  
 GCTGCCCGCAAACCGAGTTGCAAACCACTTGGGCTCAATTATTCACAACGAATACGGAAAAACCGCTTCTCG  
 AAGAATTGGGGCTGTTTCGACGGTCCGGATCAGGACAACGGGCTTATTCTTATTTGGGCGGTTAAGGGCGATAAA  
 GGGCTGCTGCCCAAAATCAACCATCGTCCAACCGGCCGGCAGCCATATTCAACACGTCTACTTCGATGCCGCGCT  
 CAAAAAAGACATTACCGTTAAACTACAGCACCAATACCGTCGGTACCGTTCGGCGGAATATAACGGCTATTACG  
 GCTCGGATGACGAATTAAAGCGGGATTGGAGAAAACCGCCACATACAAGAACATTGCAACCAGAGCTGCCAATT  
 TATGAACCGTATTGAAAAAATACGGCAAAAGCGGCCAACACCATTGGTACGCATTAGTGGACTTCGGCAGTTA  
 TTTCATGCCGTTGCCAGCTATTGGCACACACCGTATGCCAACATCCAAGAAATGTATTTCCAAATGGCGACT  
 CGGCGTTACACCGCCTAAAACCAGAGCGCGAACACTGGCAATTGGCTCAATACCTATAAAAAGGATTGTTA  
 AAACAAGATGATACATTAGGATTAACACTGGTGGCTACCGCAGCCATCGACAACATACATCCACAACGTTACGGAA  
 ATGGTGGATTGAAACGGAATTCCGAGCTGGTACGCAGCACGGGTTGCTACACCATCCAACACCGCAATTCA  
 AAGACAAAGTACACAAACACGGTTTGAGTTGGAGCTGAATTACGATTATGGGCTTTTACCAACCTTCTACGCC  
 TATCAAAAAGCAGCAACCGACCAACTTCAGCGATGCCAGCGAATGCCAACAAATGCGTCAAAGAACCAACTCAA  
 ACAAGGTTATGGGTGAGCAGGGTTCCGCCCTGCCGAGATTACGGACGTTGGAAGTCGGTACGCCGTGGTGGGCA  
 ACAAAAGTACTTGGCGGCCGATGCCCTATTGGCAAGAGCATCCGCGACGGCTGAAGAACGCTATATGCC  
 ACCAACGGGGAAATACCAGCAATGTCGGCAACTGGCAAGCGTCCATCAAACAAACCGAACCCCTGCCAGCC  
 TTTGATTTTGTATTTACGCCGTTACGAGCGAAGAAAACCTTATTTCCGCGCGAAGTCAAATCTGTCGACA  
 GGCGTTATATCGATCCGCTCGATGCCGAAATGATGCCGACGCAGCTATTACAGTTCGACCCGAAAGACAAG  
 GACGAAGAAGTAACGTGAATGCTGATAAAACGTTGTCAACGGCAAATACGGGGCACAAGCAAAGCGTATTGACCAA  
 TTTGCACGCCGACCTTTGATAACGATGAGCTACAAGTTTAA

**SEQ ID NO:4**

*Neisseria meningitidis* BASB024 polypeptide sequence deduced from the polynucleotide of SeQ ID NO:3

MRSSFRLKPICFYLMGVMLYHHSYAEAGRAGSEAQIQVLEDVHVAKRVPDKKVFTDARAVSTRQDIKSSENLDNIV  
 RSIPGAFTQQDKSSGIVSLNIRGDSGFGRVNTMDGITQTFYSTSTDAGRAGGSSQFGASVDSNFIAGLDVVKGSFSGSA  
 GINSLAGSANLRTLGVDDVVQGNNTYGLLKGLTGTNSTKGNAMAAIGARKWLESGASVGVLYGHRSRRSVAQNYRVGGGG  
 QHIGNFGAELYERRKQRYFVQEGGLKFNSNSGKWERDFQRPYWKTKWYQKYNDPQELOQKYIEGHDKSWRENLAPOYDITP  
 IDPSSLKQQSAGNLFKLEYDGVFNKYTAQFRDLNTKIGSRKIINRNYQFNYGLSNSYANLNLTAAYNNSGRQKYPKGSKF  
 TGWGLLKDFTETYNNAKILDLNNTATFRLPRETELQTTLGPNYFHNEYGKNRFPEELGLFFDGPQDNGLYSYLGRFKGDK  
 GLLPQKSTIVQPAGSQYFNTFYFDAALKDIYRLNYSNTVGYRGGEYTGYGSDDEFKRAFGENSPTYKKHCNQSCGI  
 YEPVLKKYGKKRANNHSVISADFGDYFMPFASYSRTHRMPNIQEMYFSQIGDSGVHTALKPERANTWQFGFNTYKKGLL  
 KQDDTLGLKLVGYRSRIDNYIHNVYGKWWDLNGNIPSWVSSTGLAYTIQHRNFKDVKVHKHGELELNYDYGRFFTNLSYA  
 YQKSTQPTNFSDASESPNNASKEDQLKQGYGLSRVSALPRDYGRLEVGRTRWLGNKLTGGAMRYFGKSIRATAEERYIDG  
 TNGGNTSNVRQLGKRSIKQTETLARQPLIFDFYAAYPEKKNLIFRAEVKNLFDRRYIDPLDAGNDAATQRYYSSFDPKDK  
 DEEVTCNADKTLNCNGKYGGTSKSVLTNFARGRTFLITMSYKF

## SEQ ID NO:5

*Neisseria meningitidis* BASB024 polynucleotide sequence from strain H44/76

ATGAGATCTTCTTCGGTTGAAGCCGATTGTTTAcCTTATGGGTGTTAcGCTATATCAttATAGTTATGCCGAAGA  
 TGCAGGGCGCGCGGGCAGCGAGCGCAGATAACAGGTTTGGAAAGATGTCAACGTCAGCGAAGCGCTACCGAAAGACA  
 AAAAAGTGTACCGATGCGCGTGCCTATCGACCCGTAGGATATATTCAAATCCAGCGAAAACCTCGACAACATCGTA  
 CGCAGCATCCCCGGTGCCTTACACAGCAAGATAAAAGCTGGGATTGTCTTGAATATTGCGGGCACAGCGGGTT  
 CGGGCGGGTCAATACGATGGTGACGGCATCACGAGACCTTTATTGACTTACCGATGCGGGCAGGGCAGGGCGGTT  
 CATCTCAATTGGTGCATCTGTCGACAGCAATTATTGCGGACTGGATGTCGTCAAAGGCAGCTTCAGCGGCTCGGCA  
 GGCATCAACAGCCTGGGTTGGCGAACATCTGGGACTTTAGGCGTGGATGACGTCGTTAGGGCAATAAACCTACGG  
 CCTGCTGCTAAAGGTCTGACCGGACCAATTCAACCAAAGGTAATGCGATGGCGCGATAGGTGCGCGCAAATGGCTGG  
 AAAGCGGAGCATCTGCGGTGCTTACGGGACAGCAGCGCAGCGTGGCGCAAATTACCGCGTGGCGGGCGGGCGGG  
 CAGCACATCGGAAATTGGCGCGGAATTGGAACGGCGCAAGCAGCGATATTGTACAAGAGGGTCTTGAATT  
 CAATTCCGACAGCGAAAATGGGAGCGGGATTACAAAGGCAACAGTGGAAATACAAGCGTATAAAAATTACAACACC  
 AAGAACTACAAAATACATGAAAGGTATGACAAAAGCTGGGGAAACCTGGCGCGCAATACGACATCCCCCATC  
 GATCCGTCAGCCTGAAGCAGcagtccggcAGGCAATCTGTTAAATTGGAATACGACGGCGTATTCAATAAACACGGC  
 GCAATTTCGCGATTAAACACAAAATCGGAGCCGAAATTCAACCGCAATTATCAgTTCAATTACGGTTTgTCTT  
 TgAACcCgTATACCAACCTCAATCTGACCGCAGCCTACAATTGGGAGGGCAGAAATATCCGAAAGGGTCAAGTTACA  
 GGCTGGGGCTTTAAAGGATTGAAACCTACAACACCGAAAATCCTGACCTCAACAAACACCGCCACCTTCCGGCT  
 GCCCCCGGAAACCGAGTTGCAAACCACTTTGGGCTTCATTATTCCACACGAAATACGGAAAACCGCTTCTGAAG  
 AATTGGGCTGTTTCGACGGCTCTGATCAGGACAACGGGCTTTATTCTATTGGGGCGGTTAAGGGCGATAAGGG  
 CTGCTGCCCAAAATCAACCATTGTCACCGGCCGAGCCAAATTCAACACGTTCTACTTCGATGCCGCGCTCAA  
 AAAAGACATTACCGCTTAAACTACAGCACCAATACCGCTGGCTACCGTTGGCGGAATATACGGCTATTACGGCT  
 CGGATGACGAATTAAAGCGGGATTGGAGAAAACCGCCGACATACAAGAAACATTGCAACCGAGCTGGGATTATT  
 GAACCCGATTGAAAAAAATACGGCAAAAGCGCGCAACACCGATTGGTCAAGCATTAGTGGGACTTCGGGATTATT  
 CATGCCGTTGCCAGCTATTGCGCACACACCGTATGCCAACATCCAAGAAATGTATTTCGAAATCGGACTCCG  
 GCGTTCACACCGCCTTAAACAGAGCGCAGACACTGGCAATTGGCTTCATAACCTATAAAAAGGATTGTTAAA  
 CAAGATGATAACATTAGGATTAACCTGGCTGGCTACCGCAGCCGATCGACAACATCCACAACGTTACGGGAAATG  
 GTGGGATTGAAACGGGATATTCCGAGCTGGTCAGCAGCACCGGCTTGCCTACACCATCCAACATCGCAATTCAAAG  
 ACAAAAGTCACAAACACGGTTTGAGTTGGAGCTGAATTACGATTATGGGCGTTTTCACCAACCTTCTACGCCAT  
 CAAAAAAGCACGCAACCGACCAACTTCAGCGATGCGAGCGAATGCCAACATGCGTCAAAGAACCGAAACTCAAACA  
 AGGTTATGGGTTGAGCAGGGTTCCGCCCTGCCGAGATTACGGACGTTGGAAAGTCGGTACCGCTGGGCAACA  
 AACTGACTTGGCGCGATGCGTATTGCGCAAGAGCATCCGCGACGGCTGAAGAACGCTATATCGACGGCACC  
 AACGGGGAAATACCGCAATTCCGGCAACTGGCAAGCGTTCCATCAAACAAACCGAAACTCTGCCGCCAGCCTT  
 GATTTTGATTTTACGCCCTACGAGCGAAGAAAACCTTATTTCGCCGCCAGTCAAGTCAAAATCTGTTGACAGGC  
 GTTATATCGATCCGCTCGATGCGGCAATGATGCGGCAACGCGAGCGTTATTACAGCTCGTTCGACCCGAAAGACAAGGAC  
 GAAGACGTAACGTGTAATGCTGATAAAACGTTGTGCAACGGCAAATACGGCGGACAAGCAAAGCGTATTGACCAATT  
 TGCAACGGGACCGCACCTTTGATAACGATGAGCTACAAGTTTAA

**SEQ ID NO:6**

*Neisseria meningitidis* BASB024 polypeptide sequence deduced from the polynucleotide of Seq ID NO:5

MRSSFRLKPICFYLMGVTLHYHYSYAEAGRAGSEAQIQVLEDVHVAKRVPDKKVFTDARAVSTRQDIKSSENLDNIV  
 RSIPGAFTQQDKSSGIVSLNIRGDSGFGRVNTMVDGITQTFYSTSTDAGRAGGSSQFGASVDSNFIAGLDVVKGSFSGSA  
 GINSLAGSANLRTLGVDDVVQGNNTYGLLLKGLTGTNSTKGNAMAIGARKWLESGASVGVLGHGSRRSVAQNYRVGGGG  
 QHIGNFGAELYERRKQRYFVQEGALKFNNSDGKWERDLQRQQWKYPYKNYNQELQKYIEGHDKSWRENLAPOYDITPI  
 DPSSLKQQSAGNLFKLEYDGVFNKYTAQFRDLNTKIGSRKIINRNYQFNYGLSLNPYTNLNLTAAYNSGRQKYPKGSKFT  
 GWGLLKDFETYNNAKILDLNNTATFRLPRETELQTTLGPNYFHNEYGKNRFPEELGLFFDGPQDNGLYSYLGRFKGDKG  
 LLPQKSTIVQPAGSQYFNTFYFDAALKDIYRLNYSTNTVGYRGGEYTGYGSDEFKRAFGENSPTYKKHCNRSCGIY  
 EPVLKKYGKKRANNHSVISADFGDYFMPFASYSRTHRMPNIQEMYFSQIGDSGVHTALKPERANTWQFGFNTYKKGLK  
 QDDTLGLKLVGYRSRIDNYIHNVYGKWWDLNGDIPSWSSTGLAYTIQHRNFKDVKHGFELELNYDYGRFFTNLSYAY  
 QKSTQPTNFSDAESPNNASKEDQLKQGYGLSRVSALPRDYGRLEVGRWLGNKLTGGAMRYFGKSIRATAEERYIDGT  
 NGGNTSNFRQLGKRSIKQETLARQPLIFDFYAAYPEKKNLIFRAEVKNLFDRRYIDPLADGNDAAATQRYYSSFDPKDKD  
 EDVTCNADKTLNGKYGGTSKSVLTNFARGRTFLITMSYKF

**SEQ ID NO:7**

GCT AGC TAG CAG ATC TTC TTT CGG GAA GAA

**SEQ ID NO:8**

GGT CGC TCG AGA AAC TTG TAG CTC ATC GTT ATC A

**SEQ ID NO:9**

*Neisseria meningitidis* polynucleotide sequence up-stream the BASB024 gene sequence, in strain ATCC 13090

TATCCGATAAGTTCCGTACCGAACAGACTAGATTCCGCCTGCGCGGGAAATGACGATTCTATAAGTTCCGAAATTCCA  
 ACATAACCGAAACCTGACAGTAACCGTAGCAACTGAACCGTATTCCCACGAAAGTGGGAATCTAGAAATGAAAGCAAC  
 AGGCATTATCGGAAATAACTGAAACCGAACAGACTAGATTCCGCCTGCGCGGGAAATGACGATTCTATAAGTTCCGAA  
 ATTCCAACATAACCGAAACCTGACAGTAACCGTAGTAACTGAACCGTATTCCCACGAAAGTGGGAATCTAGAAATGAAA  
 AGCAACAGGCATTATCGGAAATAACTGAAACCGAACAGACCTAGATTCCGCCTGCGCGGGAAATGACGGCTGCAGATGC  
 CCGACGGCTTTATAGCAGATTAACAAAAATCAGGACAAGGGCGCGAGCCACAGACAGTACAAACAGTACCGAACCGATT  
 CACTTGGTCTTCAGCACCTTAGAGAATCGTTCTTTGAGCTAAGGCAGACAACGCCGACTGGTTTTGTTAATCCG  
 CTATATTCCGCATCTCTAAGATTACAGCGATAACCGGTAAATTAGGAATGGCGAACCGTCATTCCGCCACTTT  
 CGTCATTCCACCACCTTCGTATTCCGCAGGGAAATCTAGAATCTGGACTTTAGATAATCTTGAATATTG  
 CTGTTGTTCTAAGGTTAGATTCCCTTGCGCGGGAAATGACGATTCTATAAGTTCCGAAATTCAAACATAACCGAAACC  
 TGACAGTAACCGTAGAACAGAGAATCGTTCTTTGAGCTAAGGCAGAACACGCTGTACCGGTTTTGTTAATCCACT  
 ATAAATATCCAATTGAAATCTTCAGACGGTATATCGAATTACACTTTAATGTTATGCCGCTAAAAAAATGCTAAT  
 ATATTCTTAATTGCTGACTGTTATTGTTGAGGAAAT